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RESUMO 
 
Introdução 
O processo de remodelagem cardíaca é influenciado pela sobrecarga hemodinâmica, 
ativação neuro-hormonal e outros fatores ainda não totalmente esclarecidos. O miócito é a 
principal célula envolvida, mas outros componentes da remodelagem são: o interstício, os 
fibroblastos, o colagénio e vascularização coronária. Além disso, outros processos importantes 
são: a isquemia, a necrose celular e a apoptose. Quando a remodelagem ventricular está 
avançada, é autossustentável e conduz à progressão da doença, independentemente do estado 
neuro-hormonal. Este facto explica porque é que as terapêuticas medicamentosas perdem a 
sua eficácia na insuficiência cardíaca (IC) terminal e algumas terapêuticas baseadas em 
dispositivos (como a ressincronização cardíaca ou a assistência ventricular mecânica) têm sido 
benéficas. A reversão da remodelagem ventricular como determinante do prognóstico não está 
definida e os seus mecanismos moleculares não foram totalmente investigados. 
A remodelagem reversa do ventrículo esquerdo (RRVE) é caracterizada pela diminuição 
das dimensões do ventrículo esquerdo, normalização da forma do ventrículo esquerdo e 
melhoria da fração de ejeção (FEVE). Existem relatos de uma prevalência significativa de 
recuperação da função ventricular esquerda em pacientes com miocardiopatia dilatada (MCD). 
Contudo, estes estudos incluíram doentes com MCD recente, como miocardite aguda, ou com 
outras causas reversíveis de MCD, como a MCD periparto ou associada ao abuso de álcool. Os 
mecanismos subjacentes da RRVE nestas situações parecem ser diferentes dos envolvidos na 
MCD crónica idiopática. Os seus fatores preditores poderão discriminar os pacientes nos quais 
a FEVE pode recuperar com a terapêutica médica, daqueles que podem necessitar de 
estratégias mais agressivas. Nos pacientes com recuperação da função ventricular esquerda 
não está indicada a terapêutica com cardio-desfibrilhador implantado (CDI) ou 
ressincronização cardíaca (CRT), questionando-se o tempo de implantação destes dispositivos. 
Também existe um insuficiente estudo sobre os parâmetros ecocardiográficos detalhados da 
função miocárdica nos pacientes com FEVE normalizada após terapêutica farmacológica 
otimizada. 
Os biomarcadores da remodelagem da matriz extracelular, de apoptose e de 
inflamação emergiram como potenciais indicadores na identificação de indivíduos com maior 
risco. Uma vez que a remodelagem do VE parece envolver vias fisiopatológicas diferentes, um 
painel com múltiplos marcadores poderá melhorar a estratificação de risco. 
 
Objetivos 
O principal objetivo deste trabalho foi o estudo prospetivo da recuperação da função 
ventricular esquerda ou reversão da remodelagem ventricular esquerda nos pacientes com 
MCD idiopática crónica, após a terapêutica medicamentosa otimizada. Procurou-se determinar 
a sua prevalência, encontrar os seus fatores preditores e verificar se esta se associou a um 
melhor prognóstico. Pretendeu-se também estudar de forma aprofundada os mecanismos 
ecocardiográficos de remodelagem reversa. 
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Outro objetivo foi o estudo detalhado de biomarcadores acessíveis na prática clínica e 
de biomarcadores experimentais. Procurou-se encontrar associações entre estes, a RRVE e 
parâmetros de gravidade clínica.  
 
Métodos 
Foram selecionados para o estudo 113 pacientes adultos consecutivos com MCD 
idiopática (diâmetro diastólico ventricular esquerdo (LVDD) > 33 mm/m2 em homens ou >32 
mm/m2 em mulheres), seguidos na Consulta de Insuficiência Cardíaca do Serviço de 
Cardiologia do Centro Hospitalar São João, com diagnóstico estabelecido há menos de 2-3 
anos e com dois valores iniciais de FEVE<0,40, com mais de um ano de separação. Foram 
excluídos os pacientes com MCD de etiologia secundária. A RRVE foi definida como um aumento 
de 10 unidades da FEVE e diminuição do LVDD na ausência de CRT ou de assistência ventricular 
mecânica. Realizaram-se ecocardiogramas transtorácicos seriados, análises sanguíneas com 
biomarcadores, prova de exercício cardiopulmonar (CPET) e ressonância magnética cardíaca 
(MRI). 
Realizou-se um estudo ecocardiográfico detalhado (n=50, em ritmo sinusal) de análise 
morfológica, de função sistólica e diastólica, com quantificação da performance miocárdica 
(índices de Tei do VE e VD) e o estudo do strain rate sistólico longitudinal (SSR long) e 
circunferencial (SSR circ). 
Foram doseados os seguintes biomarcadores (n=50): adrenalina, noradrenalina, 
renina plasmática, aldosterona e peptídeo natriurético tipo B (BNP) (ativação neuro-hormonal), 
proteína C reativa de alta sensibilidade (hsCRP), antigénio CA-125 (inflamação), ácido úrico e 
Lp (a) (stress oxidativo), creatinina e cistatina C (função renal), 25-OH-vitamina D 
(remodelagem extracelular). Também avaliámos o perfil de biomarcadores experimentais, tais 
como: i) marcadores de remodelagem da matriz extracelular (ECM)- metaloproteinase da 
matriz 3 (MMP-3), inibidor tecidular da metaloproteinase-2 de matriz (TIMP-2), proteína ST2 
(receptor de interleucina 33) e Galectina-3; iii) marcadores de inflamação - receptor TNF 
I/TNFRSF1A (sTNF-R1); e iv) factor de diferenciação de crescimento 15 (GDF-15), um 
marcador de apoptose. 
 
Resultados 
A RRVE ocorreu em 34,5% dos pacientes numa mediana de 22,6 meses de 
seguimento. Os fatores preditores de RRVE (na análise univariada) foram: hipertensão arterial 
de grau ligeiro, fibrilhação auricular, hipertrofia ventricular esquerda no ECG, ausência de 
bloqueio completo de ramo esquerdo, menor duração do intervalo QRS, maior valor de 
hematócrito, menor LVDD indexado à superfície corporal (LVDDi), maior eficiência de oxigênio 
no pico de exercício (VO2/Log10(VE)) e menor declive VE/VCO2/VO2, tratamento com 
IECA/ARB e uso de doses máximas de IECA /ARB e bloqueadores-β. A análise multivariada 
mostrou que o uso de doses máximas de IECA/ARB foi preditor independente de RRVE. A 
presença de realce tardio (não isquémico) na MRI cardíaca não foi um preditor de RRVE. Os 
pacientes com RRVE apresentaram melhor capacidade funcional da NYHA (classe I) e menor 
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valor do BNP em comparação com os pacientes que não tiveram RRVE.  Esta esteve associada 
a menor número de hospitalizações por IC, morte cardíaca ou transplante urgente. 
Nos pacientes com RRVE houve uma diminuição significativa no LVDDi, diâmetro 
sistólico do VE, volumes diastólico e sistólico do VE, massa do VE e um aumento do índice de 
esfericidade. Entretanto, as medidas da função diastólica (LAVi, velocidade e', E/e'), índices 
de Tei do VE não foram significativamente diferentes dos valores basais. Adicionalmente, os 
valores finais do SSR circular e do SSR long não foram diferentes dos níveis basais. Os 
pacientes que recuperaram a FEVE >50%, o SSR circ e SSR long foram inferiores aos valores 
normais. 
Não se encontrou nenhuma associação entre o BNP, 25-OH-vit D, CA 125, hsCRP, Lp 
(a), noradrenalina, adrenalina, renina, aldosterona e a RRVE; contudo, os pacientes em classe 
mais avançada de NYHA (III-IV), com congestão pulmonar ou edema apresentaram níveis 
mais elevados de CA 125, cistatina C, BNP e hsCRP. Os doentes com RRVE apresentaram 
valores basais mais baixos de Galectina-3. O BNP correlacionou-se diretamente com LVDD, 
volume diastólico do VE, PSAP e E/e'; foi inversamente correlacionado com a FEVE e a 
velocidade da onda e´. O CA 125 correlacionou-se positivamente com o volume da aurícula 
esquerda/superfície corporal (LAVi), relação E/A e PSAP (r=0,49).  O valor da MMP-3 aumentou 
significativamente, ao longo do seguimento, na população total, tanto nos pacientes com ou 
sem RRVE. O GDF-15 aumentou (marginalmente) nos doentes que recuperaram a FEVE. O 
GDF-15 correlaciou-se com E/e '; o TIMP-2 correlacionou-se com LVDVi, LAVi (r = 0,28, p = 
0,02) e com o índice de esfericidade.  
 
Conclusões 
A RRVE ocorreu em cerca de um terço dos pacientes com MCD idiopática, mais 
frequentemente naqueles com perfil tensional mais elevado e com doença menos avançada, 
que poderão ter beneficiado da titulação máxima dos fármacos.  
Nos pacientes com LVRR houve melhoria dos volumes do VE e do índice de 
esfericidade, confirmando de forma “verdadeira” a remodelagem reversa do VE. Apesar da 
recuperação da FEVE para "valores normais", persistiram valores anormais de strain rate 
sistólico circunferencial e longitudinal, e valores anormais da função diastólica e do índice de 
Tei do VE, sugerindo disfunção subclínica persistente. 
O CA125, BNP, hsCRP foram preditores de gravidade clínica, de congestão pulmonar e 
sistémica. Os valores basais mais baixos de galectina-3 poderão ser um preditor de RRVE e 
postula-se que a galectina-3 pode ter um impacto negativo na função cardíaca. Na análise dos 
níveis basais e finais de biomarcadores, houve uma queda significativa no BNP; mas alguns 
biomarcadores, particularmente GDF-15 e MMP-3, continuaram a aumentar, apesar da 
terapêutica da HF, mesmo em pacientes com LVRR. Podemos especular que, apesar da 
remodelagem reversa, há ativação persistente da ECM, apoptose e atividade inflamatória. 
Foram encontradas correlações significativas entre os níveis de biomarcadores e os parâmetros 
ecocardiográficos da remodelagem do VE, apoiando a via multidirecional de remodelagem na 
IC. 
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O relato de um caso clínico de recuperação da FEVE acompanhada de um evento 
arrítmico major, aponta para a hipótese de a remodelagem reversa mecânica do VE não ser 
sinónimo de remodelagem reversa elétrica, persistindo o risco arrítmico. Recomenda-se assim 
a continuação da terapêutica medicamentosa e manutenção da terapêutica com dispositivos 
cardíacos de prevenção de morte arrítmica, nos pacientes com FEVE recuperada.  
Múltiplas linhas de evidência sustentam que, na maioria dos casos, a remodelagem 
reversa não conduz a um coração normal, apesar da reversão de muitos aspetos do fenótipo 
da IC. Assim, a regressão do fenótipo de IC e a recuperação no sentido de uma forma e de 
uma função ventricular sistólica normalizada não significa que a biologia celular/molecular e a 
fisiologia desses corações sejam normais. Isso poderá explicar porque é que a remodelagem 
reversa pode ser acompanhada por recorrência de dilatação e disfunção do VE, com resultados 
clínicos desfavoráveis. 
Estes achados têm implicações futuras no desenvolvimento de terapêuticas que 
reparem de forma completa o miocárdio insuficiente. O reconhecimento deste novo fenótipo 
clínico, conhecido como um estado de remissão da IC, ressalta a necessidade de definir e 
identificar com precisão o miocárdio com remodelagem reversa para o estabelecimento da 
terapêutica mais apropriada. 
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ABSTRACT  
 
 Introduction 
The process of cardiac remodeling is influenced by hemodynamic load, neurohumoral 
activation, and other factors that are not well understood. The myocyte is the major cardiac 
cell involved in remodeling, but other components include the interstitium, fibroblasts, collagen 
and coronary vasculature. Also, important processes are ischemia, cell necrosis and apoptosis.  
When ventricular remodeling is advanced, it is self-supporting and conducts to progression of 
the disease, independently of neurohormonal status. This explains why medical therapies lose 
their effectiveness in terminal HF, and some device-based therapies (like cardiac 
resynchronization or mechanical ventricular assistance) have been beneficial. The significance 
of ventricular remodeling as a prognostic determinant is not defined and molecular 
mechanisms of reverse remodeling have not been fully investigated.  
Left ventricular reverse remodeling (LVRR) is defined by a decrease of left ventricular 
dimensions, normalization of left ventricular shape and improvement of ejection fraction (EF). 
A significant prevalence of recovery of left ventricular function in patients with dilated 
cardiomyopathy (DCM) has been reported. However, these studies included patients with new-
onset DCM like acute myocarditis or other reversible causes of DCM, such as peripartum and 
alcohol-related DCM. Mechanisms underlying LVRR in such situations seem to be different from 
those involved in chronic idiopathic DCM. These variables probably discriminate patients in 
whom EF can recover with medical therapy only from those who may require more aggressive 
strategies. Patients whose LV function recovers no longer have indication for implantable 
cardiac defibrillator (ICD) or resynchronization therapy (CRT), thus complicating the timing of 
implantation of these devices.  
 There is also insufficient research about detailed echocardiography parameters of 
myocardial function in patients with normalized EF after optimal pharmacologic therapy. 
Biomarkers of matrix extracellular remodelling, apoptosis and inflammation have 
emerged as potential indicators to identify individuals with major risk. Because LV remodeling 
seems to involve different pathophysiologic pathways, a multimarker panel may improve risk 
stratification.  
 
Aims 
The main aim of this prospective study was to evaluate the recovery of left ventricular 
function or reversal of ventricular remodeling in patients with chronic idiopathic DCM, after 
optimized medical therapy. We tried to determine its prevalence, to find its predictors and to 
check if it was associated with better prognosis. We also intended to assess the 
echocardiographic mechanisms of reverse-remodeled cardiomyopathy. 
Another aim was to study current and experimental biomarkers of LVRR in the context 
of DCM. We tried to find associations between the biomarkers, LVRR and clinical severity.  
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Methods 
We 113 adult consecutive patients with idiopathic DCM (left ventricular diastolic 
diameter (LVDD) >33 mm/m2 in men or >32 mm/m2 in women), followed in the HF Clinic of 
Cardiology Department of Centro Hospitalar de São João, with a diagnosis of less than 2-3 
years duration and with two initial values of left ventricular ejection fraction (LVEF) of <0.40, 
more than one year apart. We excluded DCM patients with secondary etiologies. LVRR was 
defined as an increase of 10 units of LVEF and decrease of LVDD in the absence of CRT and 
ventricular assistance therapy. We performed serial transthoracic echocardiograms, blood 
laboratory measurements with current and novel biomarkers, cardiopulmonary exercise 
testing (CPET) and cardiac magnetic resonance imaging (MRI). 
We also performed an echocardiographic study in a subgroup (n=50, in sinus rhythm) 
of detailed morphological, systolic and diastolic function analysis, with myocardial performance 
quantification (LV and RV Tei indexes) and LV averaged peak systolic longitudinal strain (SSR 
long) and circumferential strain (SSR circ). 
In the biomarker substudy (n=50) we measured: adrenalin, noradrenalin, plasma 
renin, aldosterone and B-type natriuretic peptide (BNP) (neurohormonal activation), high-
sensitivity C-reactive protein (hsCRP), cancer antigen CA-125 (inflammation), uric acid and 
Lp(a) (oxidative stress), creatinine and cystatin C (renal function), 25-OH-vitamin D 
(extracellular remodeling). We also evaluated the profile of emerging biomarkers, such as i) 
markers of ECM remodeling including matrix metalloproteinase -3 (MMP-3), tissue inhibitor of 
matrix metalloproteinase- 2 (TIMP-2), protein ST2 (receptor for interleukin 33) and Galectin-
3; ii) markers of inflammation such as soluble TNF receptor I/TNFRSF1A (sTNF-R1); and iv) 
growth-differentiation factor 15 (GDF-15), a marker of apoptosis.  
  
Results 
LVRR occurred in 34.5% within 22.6 months.  Univariate predictive factors of LVRR 
were: mild hypertension, atrial fibrillation, ventricular hypertrophy on EKG, absence of LBBB, 
shorter QRS duration, higher hematocrit, lower LVDD/BSA (LVDDi), higher oxygen efficiency 
at peak exercise (VO2/LG10 (VE)) and a lower dVE/VCO2/VO2, treatment with ACEI/ARB and 
use of maximal doses of ACEI/ARB and β- blockers. Multivariate regression analysis showed 
that the use of higher doses of ACEI/ARB was independently associated with LVRR. The 
analysis of non-ischemic delayed enhancement in cardiac MRI was not a predictor of LVRR. 
Patients with LVRR had a better NYHA functional capacity (class I) and had lower BNP 
compared to those without LVRR. LVRR was associated with lower rates of HF hospitalization, 
cardiac death or urgent transplantation.  
In patients with LVRR, there was a significant decrease in:  LVDDi, LV systolic 
diameter/BSA, LV diastolic volume, LV systolic volume, LV mass; an increase in sphericity 
index. However, measures of diastolic function (LAVi, e´velocity  and E/e´ratio), final LV and 
RV Tei indexes were not significantly different from baseline. Additionally, final SSR circ and 
SSR long values were not different from basal. Patients who recovered EF> 50% SSR circ and 
SSR long were inferior to normal. 
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No association was found between BNP, 25-OH-vit D, CA 125, hsCRP, Lp (a), 
noradrenalin, adrenalin, renin, aldosterone and LVRR; however, patients in NYHA class (III-
IV), with pulmonary congestion or ankle oedema had higher levels of CA 125, cystatin C, BNP 
and hsCRP. Patients with pharmacological LVRR had lower baseline values of galectin-3.  BNP 
correlated directly with LVD, LV volumes, PSAP and E/e´; and was inversely correlated to LVEF 
and e´velocity.  CA 125 positively correlated with left atrium volume/BSA (LAVi), E/A ratio and 
PSAP (r=0,49).  MMP-3 increased in the overall population, both in patients with or without 
LVRR. GDF-15 correlated with E/e'; TIMP-2 correlated with LVDVi, LAVi (r=0.28, p=0.02) and 
sphericity index. MMP-3 had a positive correlation with LVEF. GDF-15 increased (marginally) 
in patients who recovered LVEF. 
 
Conclusions 
LVRR occurred in about one third of IDCM patients, especially in those with higher 
blood pressure and with less advanced disease, which may benefit of maximal drug titration.  
In patients with LVRR there was an improvement of diastolic and systolic volumes and 
in sphericity index, confirming truly LV reverse reshaping.   Besides recovery of left ventricular 
ejection fraction to “normal values”, there is still abnormal circumferential and longitudinal left 
ventricular strain rate and left ventricular Tei index values, suggesting persistent subclinical 
left ventricular dysfunction. 
 CA125, BNP and hsCRP were predictors of clinical severity and congestion. Lower 
baseline values of Galectin-3 may be a predictor of LVRR in DCM patients and we postulate 
that galectin-3 may have negative impact on cardiac function.   
In the analysis of basal and final levels of biomarkers in our population, there was a 
significant decrease in BNP; but some biomarkers, particularly GDF-15 and MMP-3, continued 
to rise, despite HF therapy, even in patients with LVRR. We can speculate that despite 
ventricular reverse remodeling, there is persistent matrix fibrosis activation, apoptosis and 
inflammatory activity. Significant correlations were found between the levels of biomarkers 
and echocardiographic parameters of LV remodeling, supporting the multidirectional pathway 
of remodeling in HF. 
The report of LV recovery case with a major arrhythmic event point the hypothesis 
that LV mechanical reverse remodeling is not always followed by LV electrical reverse 
remodelling, with persistence of arrhythmic risk.  Our believe is to continue background 
medical or device therapy for sudden death in HF-Recovered patients.  
Multiple lines of evidence support the point of view that in most instances, reverse 
remodeling does not lead to a normal heart, despite reversal of many aspects of the HF 
phenotype. Thus, the regression of the HF phenotype and the accompanying return toward a 
more normal ventricular shape and function does not signify that the cellular/molecular biology 
and physiology of these hearts is normal. This may explain why reverse remodeling may be 
followed by recurrence of LV dilatation and dysfunction with poor clinical outcomes. These 
findings have implications for future research to develop therapies to repair fully the failing 
myocardium. Recognition of this new clinical phenotype, which is coming to be known as a 
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state of HF remission, underscores the need to accurately define and identify reverse modelled 
myocardium in order to investigate the most appropriated therapies. 
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1. HEART FAILURE MECHANISMS  
Heart failure (HF) is one of the most relevant causes of morbidity and mortality in the 
industrialized world (1). This syndrome carries a mortality of ≈50% at 5 years, and its 
incidence and prevalence are expanding around the globe (2). The prevalence of symptomatic 
HF is estimated to range from 0.4 to 2.0% in general European population (3). The lifetime 
risk of HF at age 55 years is 33% for men and 28% for women (4, 5). The estimated lifetime 
cost of HF per individual patient is $110,000/year, with more than three-fourths of this cost 
related to hospital care (6). Despite the improvement in therapeutics, the 5-year mortality is 
still approximately 50%, which is worse than many cancers (7). 
HF is triggered by an initial event that can be abrupt, such an acute myocardial 
infarction, or insidious like: pressure or volume overload, genetic or toxic factors. The common 
feature of each of these events is that they all produce a decline in ventricular function (8). In 
Figure 1. is presented a scheme of Heart Failure Mechanisms, based from text of Mann et 
al.(8). 
 
 
 
 Figure 1- Heart Failure Mechanisms 
 Sandra Amorim- Personal communication- XXXI Portuguese Congress of Cardiology, Joint Session with the 
 European Society of Cardiology, 2010. Adapted from text of Mann (8). 
 
Clinicians initially viewed HF as a problem of excessive salt and water retention that 
was caused by abnormalities of renal blood flow (the “cardiorenal model”). It also became 
apparent that HF was associated with a reduced cardiac output and excessive peripheral 
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vasoconstriction (cardiocirculatory model) (9). The cardiorenal models provided the rational 
basis for the use of diuretics to control the volume status, and the cardiocirculatory model 
provided the rational basis for the use of inotropes and intravenous vasodilators to augment 
cardiac output, these therapeutic strategies have not prevented HF from progressing (9-11). 
However, neither of these models explain the disease progression. 
 
   1.1 Neurohormonal compensatory mechanisms 
 Compensatory mechanisms are activated after the initial decline in the cardiac 
function, those include activation of the adrenergic nervous system and salt- and water-
retaining systems in order to maintain cardiac output (8, 12, 13). Simultaneously there is 
activation of  vasodilatory molecules, to counteract the excessive vasoconstriction resulting 
from excessive activation of the adrenergic and renin-angiotensin systems (14). 
Norepinephrine, angiotensin II, endothelin, aldosterone, and TNF are active molecules, 
sufficient to contribute to disease progression in the failing heart; vasodilators such as nitric 
oxide, natriuretic peptides, prostaglandins, and kinins, are insufficient to counteract the 
peripheral vasoconstriction. The increase in cardiac adrenergic drive through β1-adrenergic 
receptor pathways is the most powerful compensatory mechanism, with an increase in 
contractile function, in heart rate, myocyte hypertrophy, volume expansion and an increase in 
left ventricular tele diastolic volume (by signalling vasopressin release)(8, 15). 
 It may not be possible to achieve complete inhibition of the renin-angiotensin system 
or the adrenergic system in HF because of dose-limiting side effects of ACEI and β-blockers; 
there may be alternative metabolic signalling for neurohormones (conversion of angiotensin I 
to angiotensin II within the myocardium by tissue chymase); biologically active molecules may 
contribute to disease progression due to toxic effects on the heart and the circulation; some 
HF activated signalling pathways that produces harmful effects in cardiac myocytes in isolated 
systems (like endothelin or TNF-α) may have favourable effects in the complex HF scenario 
(8).  Finally, HF can progress independently of the neurohormonal status of the patient. 
 
1.2 Ventricular Remodeling  
Cardiac remodeling is due to an abnormal genomic expression that translates into 
molecular, cellular and interstitial changes leading to changes in the size, shape and function 
of the heart, in response to aggression or hemodynamic overload of the heart (16). Ventricular 
remodeling is, therefore, an important aspect in the progression of HF, additional of the 
neurohormonal state. This process is the culmination of a complex series of transcriptional, 
signalling, structural, electrophysiological, and functional events occurring within the cardiac 
myocyte (17).  
Although the term “cardiac remodeling” was initially named to describe the prominent 
changes that occur following myocardial infarction (18, 19) similar processes occur following 
other types of injury such as with pressure overload (aortic valve stenosis, hypertension), 
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inflammatory disease (myocarditis), idiopathic dilated cardiomyopathy (DCM), and volume 
overload (valvular regurgitation). 
 Pfeffer et al. introduced the fundamental concept that the structural aspects of 
remodelling are defined and quantified by shifts of the ventricular end-diastolic pressure–
volume relationship (EDPVR) a finding that was soon confirmed in human end-stage failing 
hearts obtained at the time of heart transplantation (20).  
 Different forms of myocardial aggression share molecular, biochemical and cellular 
events leading to change in the shape and function of the myocardium (8). 
 
1.2.1 Myocyte hyperplasia and hypertrophy 
Most cardiomyocytes are incapable of dividing (hyperplasia) and respond to stress with a 
hypertrophic growth response. As part of this process, a wide range of transcriptional and 
posttranslational events occur, including activation of a pattern of gene expression reminiscent 
of that observed during foetal development (foetal gene program)(2). 
Remodeling is associated with myocyte hypertrophy following increased production and 
local release of angiotensin II, noradrenaline and endothelin. Load changes cause cytoplasmic 
membrane distension and increase wall stress, which also induces the expression of genes 
associated with hypertrophy. The stretching of the myocyte membrane further increases the 
release of AII, with local increase of ACE and expression of AT1 receptors. The increase in 
angiotensin II, aldosterone and cytokines stimulate the synthesis of collagen, causing fibrosis 
and remodeling of the extracellular matrix (ECM) (21). Increased wall stress may precipitate 
an imbalance between energy intake and energy consumption, leading to ischemia and to a 
vicious cycle of functional aggravation (17). 
 
1.2.2 Alterations in myocyte biology 
The changes that occur in the biology of the failing adult cardiac myocyte include: 1) cell 
hypertrophy; 2) changes in excitation-contraction coupling leading to alterations in the 
contractile properties of the myocyte; 3) progressive loss of myofilaments (myocytolysis); 4) 
β-adrenergic desensitization; 5) abnormal myocardial energetics secondary to mitochondrial 
abnormalities and altered substrate metabolism; and 6) progressive loss and/or disarray of 
the cytoskeleton (22).  
In myocyte biology, there is a decrease in the expression of the α-myosin heavy chain 
gene with increased expression of β-myosin heavy chain, a progressive loss of myofilaments, 
changes in cytoskeletal proteins, downregulation of expression of calcium ATPase of 
sarcoplasmic reticulum (SERCA2a), changes in the contraction-excitation coupling and 
desensitization of β-adrenergic receptors. This is accompanied by the activation of a program 
of foetal cardiac genes that includes genes whose products regulate cardiac contractility and 
calcium metabolism. There is dysregulation of Ca2+ movements:  a diastolic leak of Ca2+ 
through altered RyR2 lowers the Ca2+ content of the sarcoplasmic reticulum, reducing the 
Ca2+ that can be released during activation, thereby weakening contraction (23). Another 
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major abnormality of Ca2+ fluxes is the loss of function of the SERCA2a pump, which reduces 
the Ca2+ content of the cardiac sarcoplasmic reticulum,  and the quantity the Ca2+ released 
during myocyte activation, causing systolic dysfunction and ventricular tachyarrhythmias (24). 
Additionally, stimulation of β-adrenergic receptors normally causes the 
phosphorylation of phospholamban and thereby disinhibits SERCA2a, enhancing both cardiac 
contraction and relaxation; this “contractile reserve” provided by adrenergic stimulation may 
be reduced in HF, with the desensitization of myocardial β-receptors (25). 
 
1.2.3 Myocyte death and apoptosis 
Myocyte necrosis may be caused by norepinephrine, endothelin, and circulating AII in the 
myocardial tissue. The occurrence of myocyte necrosis is suggested by studies showing that 
troponin I circulation were increased 3 to 4 times in patients with advanced heart failure (26).  
Myocardial apoptosis (programmed cell death) can be triggered by myocardial stretch, 
norepinephrine, oxidative stress, TNF-α, and angiotensin II (27, 28). As angiotensin II and 
norepinephrine can trigger apoptosis, drugs that block sympathetic nervous system and renin-
aldosterone system can reduce apoptosis (29, 30).  
In autophagy, cells digest their own intracellular proteins and lipids, a process that 
may be normal (protective) when these substances are altered and become toxic, but when 
accelerated may become maladaptive and result in increased cell death (31). Selective 
inhibitors targeting apoptosis (caspase inhibitors), necrosis (inhibitors of mitochondrial 
permeability transition pore opening), and necroptosis (necrostatin1) have been developed 
(32). However, optimal timing of therapy, targets for inhibition within apoptotic signalling 
cascades, precise mechanisms of inhibition, and even the cell types involved remain unclear 
(2). 
1.2.4 Fibrosis 
The cardiac ECM is a dynamic structure of a complex network of fires comprised of matrix 
proteins in which cardiac myocytes, leucocytes, cardiac vascular cells, and fibroblasts are 
involved. In the ECM, perivascular fibrosis occurs, as well as replacement fibrosis (8). The 
increased synthesis of ECM enhances myocardial stiffness in pressure overload hypertrophy 
and reduces the rate of ventricular relaxation as well as contraction (33). This promotes 
contractile dysfunction and rhythm disturbances. In myocardial infarction scar formation arises 
from replacement fibrosis in regions of myocyte necrosis; in hypertension, in pressure overload 
and in remote regions after myocardial infarction, fibrosis is reactive (perivascular or 
interstitial)(2). Experimental studies have shown that angiotensin II, endothelin and 
aldosterone can cause excessive fibrosis in myocardial tissue (34, 35).  
Activation of matrix metalloproteinases (MMPs) (collagenolytic enzymes) leads to a 
progressive degradation of the ECM, which in turn leads to mural realignment ("slippage") of 
myocytes in the left ventricle, which contributes to ventricular dilatation and decreases the 
thickness of the wall (8). TNF-α, cytokines and peptide growth factors can activate MMPs. 
Degradation of the matrix is also controlled by inhibitors of matrix metalloproteinase 
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glycoproteins (TIMPs). Myocardial fibrosis is associated with ECM degradation resulting from 
an imbalance between MMPs and tissue inhibitors of MMPs, favouring the latter, and causing 
excessive fibrosis (36). 
 One study showed that anti-angiotensin and anti-mineralocorticoid intervention leads 
to an increase in scar maturation while diminishing remote reactive fibrosis (37). Angiotensin 
receptor blockers (ARB) appear to have antifibrotic actions; losartan reduced fibrosis and 
serum collagen markers in hypertensive heart disease (38, 39). There is no current clinical 
evidence to suggest that fibrotic changes occurring in the myocardium are completely 
reversible (8). 
1.2.5 Vascular remodelling 
 The development of coronary collateral circulation is an important mechanism of 
vascular remodeling. Promoting angiogenesis in the setting of pressure overload can protect 
the heart from injury (40). Clinical trials of therapeutic neovascularization with gene or protein 
therapies have failed. The development of proangiogenic therapies may require a combination 
of multiple growth factors such as fibroblast growth factor-2, hepatocyte growth factor, 
monocyte chemoattractant protein-1, granulocyte macrophage colony-stimulation factor, 
platelet-derived growth factor-β, and transforming growth factor-β (2, 41). 
1.2.6 Metabolic remodelling 
There is an association between altered metabolism, insulin resistance and HF. This may 
be due to several causes: activation of the neurohormonal system;  inflammation as 
exemplified by increased tumour necrosis factor α (TNF-α) levels and its soluble receptors;  
alterations in skeletal muscle function and mass as a result of reduced physical activity;  
endothelial dysfunction; increased adipokines such as adiponectin and leptin; and  
pharmacological exacerbation insulin resistance (e.g. by diuretics) (42). 
 1.2.7 Alterations in LV chamber geometry 
Changes in the biology of the cardiac myocyte and in ECM lead to progressive LV dilatation 
and increased sphericity of the ventricle. The resultant increase in LV end-diastolic volume 
along with concomitant LV wall thinning, leads to functional ventricular afterload mismatch 
that contributes further to a decrease in stroke volume. High end-diastolic wall stress can lead 
to: 1) hypoperfusion of the subendocardium, with resultant ischemia and worsening of LV 
function; 2) increased oxidative stress with resultant activation of families of genes that are 
sensitive to free radical generation and 3) sustained expression of stretch-activated genes 
(angiotensin II, endothelin, and TNF-α) and/or stretch activation of hypertrophic pathways 
(22). The increased sphericity of the ventricle leads to functional regurgitation of the mitral 
valve. This process is associated with a continuous LV dilatation and a decline in the ejection 
fraction.   
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1.2.8  Electrophysiological remodelling 
Electrical remodeling, which is characterized by alterations in multiple electrogenic 
transport processes within the cardiac myocyte, is an important pathophysiological mechanism 
in HF. Myocardial fibrosis, with altered electrotonic coupling between cells, slowed conduction, 
and dispersion of refractoriness, enhances the proarrhythmic phenotype. In HF, 
phosphorylation of the ryanodine receptor by Ca2+/calmodulin-dependent protein kinase II, 
results in calcium leakage from sarcoplasmic reticulum.  There is a concurrent downregulated 
expression of the SERCA2a and a reduced Ca2+ uptake into the sarcoplasmic reticulum.  
Depletion of sarcoplasmic reticulum Ca2+ stores, coupled with elevations in cytoplasmic Ca2+, 
potentiates the development of ventricular arrhythmias (43, 44). 
 
1.3- Biomarkers 
There is substantial variation in the severity and prognosis of HF, ranging from mild 
disease, that is easily managed with neurohormonal blockade, to advanced illness requiring 
therapy with mechanical support or heart transplantation (45). Physicians have used 
biomarkers as additional tools to aid clinical diagnosis, treatment and better identify high-risk 
subjects (46). One of the most important areas of biomarker investigation is the role of 
biomarker profiling to better characterize the phenotype of patients who might best respond 
to therapeutic interventions be it drug or device therapies (47). 
Available biomarkers reflect multiple biological processes, including inflammation, 
oxidative stress, neurohormonal activation, vascular remodeling, myocyte injury and renal 
impairment  (36, 48, 49): 
 
1- Inflammation: C-reactive protein (CRP), TNF-α, Tumor necrosis factor-like weak inducer 
of apoptosis, Interleukin (IL) -1, IL-6, IL-10, and IL-18, Lipoprotein- associated 
phospholipase, Soluble TNF receptors, Chitinase-3-like protein, Interleukin-1 receptor 
antagonist, Midkine, Leucine-rich 2-glycoprotein, Pentraxin-3, CA-125, S100A8/A9 
complex, Osteoprotegerin, Serine protease PR3, Soluble endoglin, Adiponectin. 
 
2- Oxidative stress: Oxidized low-density lipoproteins, Myeloperoxidase, Urinary 
biopyrrins, Urinary and plasma isoprostanes, Urinary 8-hydroxy-20-deoxyguanosine, 
Plasma malondialdehyde. 
 
3- Extracellular matrix remodeling: MMPs, TIMPs, IL-6, Collagen propeptides, N-terminal 
collagen type III peptide, Myostatin, Syndecan-4, Galectin-3, Soluble receptor for 
interleukin 33 (ST2). 
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4- Neurohormones: Norepinephrine, Renin, Angiotensin II, Aldosterone, Arginine 
vasopressin/C-terminal pro-arginine vasopressin (Copeptin), Endothelin-1, Urocortin, 
Chromogranin A and B, Adrenomedullin/mid-regional pro-adrenomedullin. 
 
5- Myocyte injury and apoptosis: Troponins I and T, Myosin light-chain kinase I, Heart-
type fatty-acid binding protein, Creatine kinase-MB fraction, sFAS, FAS ligand, Heat shock 
protein-60, sTRAIL, Growth differentiation factor-15 (GDF-15). 
 
6- Myocyte stress: BNP, NT-proBNP, MR-proANP, proBNP, ST2. 
 
7- Extracardiac involvement: Red blood cell distribution width, Renal function and injury 
markers, β2-microglobulin, Urinary albumin-to-creatinine ratio, Triiodothyronine. 
 
Current guidelines recommend testing BNP or NT-proBNP (50). In study of ambulatory 
patients with chronic HF, Ky et al. (51) tested in ambulatory patients with chronic HF, the 
hypothesis that a group of 7 biomarkers (BNP, Soluble fms-like tyrosine kinase receptor, 
hsCRP,  ST2, cTnI, Uric acid, Creatinine), could be combined into a multimarker score that 
would predict the risk for an adverse outcome, defined as death, cardiac transplantation or 
placement of a ventricular-assist  device. Patients in the highest tertile of the multimarker 
score had a 13.7-fold increased risk of adverse outcomes compared with the lowest tertile. 
Shah et al (52) examined an array of biomarkers in 21 patients suffering from refractory 
cardiogenic shock receiving mechanical circulatory support with a percutaneous ventricular 
assist device. The investigators measured a panel of biomarkers reflecting multiple 
pathophysiologic processes (BNP, hsCRP, soluble tumor necrosis factor receptor-1 (sTNFR1), 
soluble Fas, soluble Fas ligand (sFasL), endothelin-1, and procollagen III N-terminal peptide 
(PIIINP)), both before and after percutaneous ventricular assist device support; ventricular 
unloading and restoration of circulation were associated with reductions in serum BNP, sFas, 
and endothelin-1 levels and increases in serum sFasL and PIIINP levels. 
Data now suggest that biomarkers may also be useful to predict or monitor left 
ventricular reverse remodeling (LVRR). A new clinical score that includes a remodeling 
biomarker, the ST2-R2 score, which contains five clinical variables (non-ischemic etiology, 
absence of LBBB, HF duration, LVEF and β-blocker treatment) and ST2. A significant 
relationship was observed between ST2-R2 scores and changes in left ventricular ejection 
fraction (LVEF) and indexed LV sizes, percentage reduction in LV end-systolic volume index, a 
similar trend was observed with diastolic parameters (53). 
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2- LEFT VENTRICULAR REVERSE REMODELING 
2.1 Spontaneous left ventricular reverse remodeling (LVRR) 
Spontaneous improvement in LVEF has long been recognized, even in the absence 
disease specific therapies. LVRR may occur spontaneously, most commonly in previously 
healthy young patients with a recent onset of symptoms, usually within 3 to 6 months of 
diagnosis (54, 55). Those patients have a higher potential of LVRR, either due to resolved 
underlying disease, as in the case of myocarditis; or due to the favorable effects of therapy. 
Kubanek and colleagues (56) reported a prevalence of 45% of LVRR at 12 months in 44 
patients with recent-onset DCM that included some patients with active and resolving 
myocarditis. Most reports of reversible cardiomyopathy are associated with treatment of 
specific causes, such as tachycardia (57) endocrine disorders, sepsis (58, 59) and myocarditis 
(54, 60) or with cessation or moderation of alcohol (61). 
 In one study, 36% of subjects with HF-Recovered LVEF did not have a documented 
reversible cause, highlighting that recovery of LV function is also common in patients with 
idiopathic cardiomyopathy (62). It is unclear whether such cases of LV recovery in the absence 
of myocarditis, tachycardia, or toxic injury reflect an unidentified transient injury (e.g. 
myocarditis) or is the success of medical treatment. 
 
2.2 The new entity- Heart Failure with Recovered ejection fraction 
Consistent with the importance of remodeling in HF is the observation that some 
medical therapies and cardiac devices that increase the survival of patients with HF may delay 
and, in some cases, even revert certain parameters of remodeling. A favorable response to 
drug therapy in clinical trials with ACEI, β-blockers and aldosterone antagonists was reported, 
with almost complete reversal of left ventricular function (63-67). These agents have 
dramatically changed the prognosis in HF and the beneficial effects are due to favourable 
impact on the biology of the myocyte.  An increase in LVEF of more than 15 units has been 
described, associated with an increase in functional capacity, an increase in cardiac index and 
a decrease in  pulmonary capillary pressure, associated with a better prognosis (65-68). 
Reversal of remodeling is also described with cardiac resynchronization therapy (CRT) 
(69-71), use of mechanical ventricular assist devices (LVADs) (72), stem cell and myoblasts 
transplantation (73).  
Studies of human hearts explanted from transplantation recipients after a period of 
mechanical circulatory support with LVADs showed for the first time that the end-diastolic 
pressure-volume relationship (EDPVR) of human end-stage failing hearts can substantially shift 
back to normal values. Such studies allowed for definitive differentiation between LV size 
reduction owing to decreased preload along a fixed EDPVR (that is, unloading) and shifts of 
the EDPVR back to normal values. The observations from this study led us to introduce the 
term “reverse remodelling” (74). 
HF with reduced ejection fraction (HfrEF) and HF with preserved ejection fraction 
(HFpEF) have different pathophysiology and treatment. According to LW Stevenson it may be 
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appropriate to classify  the population that experiences LVRR as HF-better-EF (75). This 
population of HF with a low EF that improves has been recognized as a distinct population in 
the latest American College of Cardiology Foundation/American Heart Association Guidelines, 
where it has been recommended that further investigation be devoted to optimizing therapies 
for this new diagnosis (76). Collaborative clinical and molecular study of this modern 
population will provide new insight into fundamental questions of how HF compensates and 
what can truly recover, and ultimately help us to support and sustain recovery for patients 
with HF (75). 
Contractile reserve has been suggested as a key predictor of LVRR, according to studies 
with dobutamine echocardiography (77) and positron emission tomography (78). 
 
2.3- Definitions of Recovered EF 
Some studies defined HF with recovered EF an increase to ≥40% with ≥5% absolute 
change (62), other studies considered patients whose EF improved to ≥50% (79). Other 
authors  (80, 81) defined LVRR as an LV end diastolic diameter < 55 mm and an increase 
fractional shortening≥ 25%. The majority of studies defined LVRR as an improvement of LV 
EF≥ 10% in absolute value together with a decrease in LV end diastolic dimension (≥10%) 
and a final value of LVEF ≥35%-40% (56, 59, 82). Choi et al (83) considered LVRR an absolute 
increase in LVEF ≥ 20% or ≥10% in a follow-up LVEF≥50%. 
 
2.4- Studies with Cardiac magnetic resonance imaging  
 Cardiac magnetic resonance imaging (MRI) may be useful in predicting LVRR, in 
patients with idiopathic DCM. In one study of recent-onset DCM, the lower extent of late 
gadolinium enhancement (LGE) and the higher edema ratio at cardiac MRI were the most 
important baseline predictors of LVRR (56). Another study in recent onset-DCM, sixty-eight 
patients with DCM and 19 healthy volunteers were studied; strain desynchrony index and 
fibrosis mass were independently associated with change in the LVEF over time (P ≤ 0.001) 
and LGE conferred additive value for predicting change in the LVEF beyond clinical and 
desynchrony parameters (85). 
Seventy-five patients with newly diagnosed idiopathic DCM under optimal therapy were 
assessed at baseline using LGE-MRI and endomyocardial biopsy (EMB); the former measured 
LGE area and the latter measured collagen volume fraction (CVF) as possible predictive indices 
of LVRR and cardiac event-free survival. Multivariate analysis indicated that only LGE area was 
an independent predictor of subsequent LVRR. There was no significant difference in prognosis 
between patients with CVF values above (severe fibrosis) and below (mild fibrosis) the median 
of 4.9%. The degree of myocardial fibrosis estimated by baseline LGE-CMR imaging, but not 
that estimated by baseline EMB, can predict LVRR and cardiac event-free survival in response 
to therapy in patients with newly diagnosed idiopathic DCM (86). 
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3- ANTI-REMODELING THERAPIES 
3.1 Pharmacological therapies 
3.1.1. Inhibitors of the Renin-Angiotensin-Aldosterone Axis 
Angiotensin receptor activation can induce cardiac remodeling independently of 
changes in blood pressure. Numerous clinical trials have demonstrated that ACEI and ARBs 
reduce HF morbidity and mortality (73). ACEI therapy seems to prevent the worsening of LV 
dilatation and hypertrophy, however, there is controversial if it can induce reverse remodeling. 
Captopril did not lead to a reduction in LV volume, but attenuated progressive LV dilatation, in 
59 patients after anterior myocardial infarction and baseline ejection fraction<45% (18). 
Compared to placebo, captopril, was associated with a significantly lower LV end-systolic 
volume and higher LVEF after 3 months of therapy in 100 patients after myocardial infarction 
(87). In the  echo substudy of the SOLVD trial, enalapril treatment prevented further LV 
enlargement, associated with a slight reduction in LV mass, over a follow-up period of 12 
months (65). However, in the SAVE trial, captopril attenuated LV dilatation within the first year 
after myocardial infarction, but not in the second year of follow-up (88). This indicates that 
patients may escape from the beneficial effects of ACE inhibition on maladaptive remodeling 
after prolonged periods of time.  
The large ValHeFT trial (n=5010) demonstrated that combination therapy of the AT1 
receptor antagonist Valsartan with an ACEI was more effective than ACEI therapy alone to 
induce reverse remodeling in patients with symptomatic systolic HF: both ejection fraction 
increased, and left ventricular end-diastolic dimension (LVDD) decreased significantly more 
with combined renin-angiotensin-aldosterone blockade over prolonged (>24 months) periods 
of time (89).  
The renin inhibitor Aliskiren blunts remodelling in experimentally infarcted mouse 
hearts (90), but the ATMOSPHERE study (aliskiren versus enalapril or combination)  found no 
benefit from the addition of a renin inhibitor to an evidence-based dose of enalapril (91). 
The EMPHASIS-HF study revealed that eplerenone reduces mortality and 
hospitalization in patients with systolic dysfunction and mild symptoms (92). Increased levels 
of cardiac aldosterone have been reported in experimental models of myocardial infarction, 
correlating with LV remodelling. The effects of aldosterone are like those observed with 
angiotensin II, including inhibition of nitric oxide synthase and promotion of inflammation, 
fibrosis, and cardiac myocyte apoptosis.  
Angiotensin receptor–neprilysin inhibitors are a new class HF drugs. They provide a 
new strategy of treatment named neuro-hormonal modulation by blocking the renin-
angiotension-aldosterone axis and simultaneously stimulating the counter-regulatory systems 
through neprilysin inhibition. A drug, LCZ696, combines a moiety of valsartan with sacubitril, 
a neprilysin inhibitor. In the recent PARADIGM-HF study, LCZ696 was superior to enalapril in 
reducing the risks of cardiovascular death and of hospitalization for HF (93). 
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3.1.2. β-blockers 
Hall et al. (94) reported a progressive increase in LV ejection fraction, a decrease in 
LV dilatation and hypertrophy, and LV restoration to a more elliptical shape in patients treated 
with metoprolol over a time course of 3–18 months. In a substudy of the MERIT-HF trial, 
patients treated with metopolol CR/XL were followed by cardiac MRI and a significant decrease 
in LV volumes and increase in LVEF were observed after 6 months in the metoprolol group, 
but not in the placebo group (66). Olsen et al. (95) reported LVRR in chronic HF patients 
treated with carvedilol.  In elderly patients with HF and advanced LV systolic dysfunction, 
nebivolol reduced LV size and improved LVEF as reported in the echocardiographic substudy 
of the SENIORS trial (96). A meta-analysis of all available β- blockers trials showed an average 
29% relative increase in ejection fraction, irrespective of the etiology of HF (97). In these 
studies, LVRR was observed with selective or nonselective beta-blockers, even in the presence 
of baseline therapy with an ACEI. 
The results of the REVERT (Reversal of Ventricular Remodeling with Metoprolol-LX) 
showed that metoprolol succinate therapy reverses LV remodelling and dysfunction in patients 
even with asymptomatic LV systolic dysfunction (98). 
Reverse remodeling with β-blocker therapy has also been documented at a cellular 
level in isolated human myocardium. Some beta-blockers may increase the number of β-
adrenergic receptors, which are downregulated in HF (99). Lowes et al. (100) demonstrated 
an association between normalization of myocardial gene expression for SERCA2a and β-
myosin heavy chain and the improvement in LVEF and clinical status in patients with DCM 
under β-blocker therapy. Reiken et al. (101) showed that β-blocker therapy partially restored 
diastolic filling, β-adrenergic responsiveness and ryanodine release channel function in patients 
with idiopathic or ischemic cardiomyopathy.  
Of major relevance is the contribution of adrenergic receptor polymorphisms on HF 
progression and on therapeutic response. For example, a double adrenergic receptor 
polymorphism, an Α-2C deletion/loss of function genotype (α-2C Del322-325), combined with 
a high-functioning β1-receptor genotype (β1 Arg389), confers a 10-fold risk for the 
development of HF (102). 
 
3.1.3.  Ivabradin 
Ivabradin induces LVRR in patients with HF and reduced LVEF.  In a rat model of chronic 
mild HF, ivabradine preserved cardiac output and improved LV function and geometry and 
these changes were linked to modifications in the ECM and in cardiac myocyte function (103). 
Ivabradine also had beneficial effects on the global cardiac remodelling process, including 
optimization of energy consumption, reverse electrophysiological and structural cardiac 
remodeling (104). Similar effects with ivabradine have been found by other workers in a rat 
model of chronic severe HF, including reductions in fibrosis, local renin-angiotensin stimulation, 
endothelial dysfunction and sympathetic activation (105).   
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The SHIFT echocardiographic substudy included 411 patients and evaluated ivabradine 
effect on LV remodelling, superimposed on background therapy optimal  for HF (106). 
Ivabradine reduced LV end-systolic volume index (LVSVi) vs. placebo. The reduction in LVSVi 
was independent of β-blocker use, HF aetiology, and baseline LVEF. Ivabradine also improved 
LV end-diastolic volume index (LVDVi) and LVEF. The incidence of the SHIFT primary composite 
outcome (cardiovascular mortality or hospitalization for worsening HF) was higher in patients 
with LVSVi above the median (59 mL/m2) at baseline and patients with the largest relative 
reductions in LVEVi had the lowest event rates. Finally, there was a significant inverse 
relationship between the change in heart rate and the change in LVEF, which means that larger 
decreases in heart rate during follow-up were associated with greater increases in LVEF. 
Ivabradin induced reversal of  myocardial fibrosis and improvement of deranged E-C 
coupling in rats, superior to metoprolol (107).  
3.1.4.  Novel pharmacological therapies for LV remodeling 
-   Soluble tumour necrosis factor-a (TNF-a) antagonist etanercept 
Treatment with the soluble tumour necrosis factor-a (TNF-a) antagonist etanercept 
improved LV remodelling and dysfunction in a study of patients with severe HF (108),  however 
it was not associated with an improvement in clinical outcome in larger studies (109). The 
reasons for this discrepancy are not completely understood, but may include potential adverse 
effects of TNF-a antagonism and potential beneficial effects of cytokine activation in patients 
with HF. We can conclude that not all interventions that attenuated LV remodelling had a 
beneficial effect on survival in clinical trials. 
- Modulators of Nitric oxide- cGMP and signalling pathways  
Nitric oxide (NO) at low concentrations protects cardiomyocytes from 
ischaemia/reperfusion-injury via soluble guanylyl cyclase activation and cGMP formation and 
exerts beneficial effects on LV remodelling after myocardial infarction (110).  
Takimoto et al. (111) showed that inhibition with cGMP phosphodiesterase-5A, a sustained 
activation of PKG-I can occur, thus preventing and reversing cardiac hypertrophy and 
remodeling. Approaches to stimulate NO or its signalling pathways include β-blockers with NO 
enhancing properties (like nevibolol), or NO-enhancing drugs (112). Whereas low doses of NO 
produced by eNOS exerts cardioprotective effects, large amounts of NO produced by inducible 
NO synthase (iNOS) exert detrimental effects and are not necessarily cardioprotective (113, 
114). 
- Statins and anti-oxidant strategies  
Several experimental studies showed that statins inhibit cardiomyocyte hypertrophy and 
enhance endothelial nitric oxide synthase (eNOS) activity. Thus they may play an important 
role in limiting LV remodeling (110). In an echocardiographic study by Sola et al. (115) in 108 
patients with DCM and a LVEF <35%, the use of atorvastatin improved LVEF by approximately 
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4% and reduced LVDD as compared with placebo. Krum et al. conducted a study with high-
dose rosuvastatin in 86 patients with ischaemic or non-ischaemic DCM and did not observe a 
significant change in LVEF or LVDD (116). In the CORONA Trial rosuvastatin did not 
significantly reduce the primary endpoint of death from cardiovascular causes, nonfatal 
myocardial infarction, or non-fatal stroke, nor reduce the number of deaths from any cause. 
Nevertheless, it reduced cardiovascular hospitalizations (117). A low dose of rosuvastatin was 
used which possibly was not sufficient to produce the myocardial effects required for an impact 
on LV remodeling.  
In the OPT-CHF study, Hare et al. have examined the effects of oxipurinol in 402 HF-
reduced EF patients receiving optimal medical therapy,  but the benefits only occurred in 
patients with elevated serum uric acid and in relation to the degree of uric acid reduction (118). 
- Modulators of inflammation and pro-inflammatory cytokines 
A major challenge to prevent or reverse LV remodeling is to limit detrimental 
inflammatory cell-mediated changes, while simultaneously maintaining adequate and 
appropriate LV repair responses (110). The initial remodelling phase after myocardial infarction 
leading to a removal of necrotic debris and to scar formation (infarct healing) should probably 
be considered beneficial as it serves to maintain LV structural integrity and to prevent LV 
rupture. Interference with the process of scar formation during the acute post-myocardial 
infarction period, by administration of glucocorticosteroids and non-steroidal anti-
inflammatory drugs can cause increased thinning of the infarct zone and potentially greater 
degrees of infarct expansion. Toll-like receptors (TLRs), primary innate immune receptors that 
are also activated by endogenous signals, are expressed by cardiomyocytes and vascular cells 
and two experimental studies have observed that TLR-4 activation, that is increased in HF, is 
an important mediator of maladaptive LV remodelling and dysfunction (119, 120). Another 
experimental study has shown that exogenous administration of a recombinant human 
interleukin (IL)-1 receptor antagonist (anakinra) can reduce cardiomyocyte apoptosis and LV 
remodelling after acute myocardial infarction (121). 
- Metalloproteinase inhibitors 
The PREMIER (Prevention of Myocardial Infarction Early Remodelling) trial included 253 
patients with ST-segment elevation MI (LVEF<40%). Patients were randomized to placebo or 
the oral MMP inhibitor PG-116800, a drug that previously showed significant anti-remodeling 
effects;  after 90 days of follow-up no significant effects on LV remodelling or clinical outcome 
were noted (122). An experimental study by Spinale et al. has demonstrated that MMP 
inhibition conferred a beneficial effect on survival early post-myocardial infarction, but that 
prolonged MMP inhibition was associated with higher mortality rates and adverse LV 
remodeling, suggesting that there may exist an optimal time window with respect to 
pharmacological interruption of MMP activity after an acute infarct (123). In support of this 
concept, Kelly et al. have observed a biphasic profile of plasma MMP-9 that is related to LV 
remodeling: higher early levels of MMP-9 were associated with the extent of LV remodeling, 
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but  higher plateau levels late after myocardial infarction were associated with a relative 
preservation of LV function (124). 
- Pro-angiogenetic factors and/or cell transfer  
 Bone marrow cells and hematopoietic stem cells have been implanted into the adult's 
heart, either by intracoronary injection, direct myocardial injections, or mobilized from the 
periphery through the administration of granulocyte colony-stimulating factors; but recent 
studies have question the ability of stem cells to differentiate in cardiac myocytes (125-127). 
Recent evidence has demonstrated the existence of progenitor cells resident within the 
myocardium and cardiomyocytes capable of re-entering the cell cycle, findings that contradict 
the traditional idea that the heart is a strictly postmitotic organ (2).  
The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial 
demonstrated no significant benefit from this therapy, coupled with an increased risk of 
malignant ventricular arrhythmias (128). In Stem Cell Infusion in Patients With Ischemic 
Cardiomyopathy (SCIPIO) study, LVEF increased from 30.3% to 38.5% at 4 months after 
infusion; cardiac MRI measurements of infarct size demonstrated 24% and 30% decreases at 
4 and 12 months, respectively (129). The Cardiosphere-Derived Autologous Stem Cells to 
Reverse Ventricular Dysfunction (CADUCEUS) trial showed significant reductions in scar, 
increases in viable heart mass, and improvements in regional contractility and regional systolic 
wall thickening evaluated by cardiac MRI at 6 months;  however, changes in LVDV, LVSV, and 
LVEF did not differ between groups (130). In the Pilot Study of the Comparative Safety and 
Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic 
Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction 
Secondary to Myocardial Infarction (POSEIDON), allogeneic mesenchymal stem cells  therapy 
was associated with an improvement in functional capacity; however, neither approach 
improved exercise VO2max; allogeneic or/and autologous MSCs reduced mean infarct size, 
sphericity index and LVDV but did not increase EF (131). 
3.2. Resynchronization Therapy 
Patients with asynchronous wall motion due to intraventricular conduction delay are at 
increased risk for exacerbated HF. Biventricular pacing or CRT can re-coordinate contraction, 
thereby acutely improving systolic ventricular function and energetic efficiency (132).  The 
mechanisms for LVRR with CRT remain to be understood, but may comprise: reduced wall 
stress due to reduced inhomogeneities in regional contractile activation, decreased 
sympathetic nerve activity,  increased metabolic efficiency (132, 133). In animal studies, CRT 
therapy can restore intracellular Ca2+ homeostasis, normalize the ratio of β1/β2 adrenergic 
receptors, and alter the expression of genes involved in mitochondrial energetics, ECM  and 
reduce myocardial stress  (134-136). 
Reverse remodeling with CRT was observed in the MIRACLE study, a prospective, 
double-blind randomized,  in 323 HF patients (mean EF 24±7%) on optimized medical heart 
failure therapy; CRT induced significant and progressive reverse remodeling over 6 months: 
CHAPTER II |  INTRODUCTION 
 
 
41 
LVDV and LVSV as well as mitral regurgitation decreased, associated with an increase in LVEF; 
in addition, LV mass decreased and myocardial performance and LV sphericity index improved 
(69). MIRACLE reported beneficial effects on NYHA symptom class and 6-minute walk test, 
reductions in LV volumes were found to be dependent on disease type, with greater reductions 
noted in nonischemic patients versus ischemic patients (137). 
Other trials, like the CARE-HF (Cardiac Resynchronization in Heart Failure) (138) and 
MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization 
Therapy) (71) showed that CRTs can improve symptoms and reduce mortality. These results 
were associated with improvements in LV remodelling and in LV systolic and diastolic function 
(139).   Contrary to MIRACLE study, reductions in mortality and improvements in cardiac 
function in CARE-HF were similar in nonischemic and ischemic patients (138). In order to 
optimize patient selection and identify CRT responders a multicenter trial (Predictors of 
Response to CRT [PROSPECT]) was conducted, enrolling 498 patients,  but no specific 
parameter conclusively improved patient selection criteria (140). 
3.3. LV assist device 
 The most informative data on reverse remodelling are derived from studies in the 
setting of LVAD support. LVADs showed to be able to increase LV wall thickness, decrease LV 
volume and induce a favourable leftward shift in the LV pressure-volume curve (141). A 
significant increase in contractility was demonstrated in cardiac myocytes isolated from hearts 
that have undergone LVAD support compared with myocytes isolated before LVAD support. In 
addition to these changes in cardiac myocytes, changes in the ECM and microvascular density 
(angiogenesis) were also noted.  Support with a LV assist device was shown to improve the 
force-frequency relationship of isolated strips of ventricular tissue, along with improvements 
in genes encoding for proteins involved in Ca2+ handling (SERCA 2a, the ryanodine receptor, 
and the sarcolemma sodium-calcium exchanger)(142). LV assist device support led to a 
restoration of the integrity of the dystrophin cytoskeleton, which had been shown to be 
disrupted in myocytes from failing hearts (143).  
Treatment with β-blockers and LVAD support decreased hyperphosphorylation of the 
ryanodine receptor, which has been implicated in a calcium leak from the sarcoplasmic 
reticulum in failing hearts and hence contractile dysfunction. However, tissue levels of 
angiotensin II, a profibrotic peptide, increased in patients supported by LVADs, who were not 
medicated with a ACEI (22). 
Gene expression profiling studies have shown that only 5% of genes that are 
dysregulated in failing hearts revert to normal after LVAD support, despite morphological and 
functional improvement (144, 145). Although maximal calcium-saturated force generation is 
improved in myocytes after LVAD support, force generation is still less than in myocytes from 
nonfailing controls, despite reversal of cardiac myocyte hypertrophy (146).  After LVAD, ECM 
does not revert to normal and increased myocardial fibrosis can occur. 
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3.4. Surgical approaches 
A number of different surgical approaches have been tried to prevent and/or retard LV 
remodeling, including surgical myoplasty (147), which has been abandoned, mitral valve 
surgery (148) volume reduction surgery (partial left ventriculectomy) (149) and 
endoventricular circular patch plasty/surgical anterior ventricular restoration Dor procedure 
(150). 
The CorCap device has been implanted worldwide in more than 130 patients with 
dilated cardiomyopathy (idiopathic or ischemic). During follow-up, chamber dimensions 
decreased, and ejection fraction and NYHA class improved (151). The Acorn Trial  
demonstrated sustained reverse remodeling of the LV and the long-term safety and efficacy of 
the CorCap cardiac support device as an adjunctive therapy for patients with HF who remain 
symptomatic despite optimal medical therapy (152, 153). 
3.6. Recurrence of LV systolic dysfunction 
Withdrawal of β-blockers and ACEI after LVRR may be associated with recurrence of 
systolic dysfunction  (154) or left ventricular hypertrophy (155). In a study, involving 42 
patients in whom LVEF recovered, LV systolic dysfunction reappeared during the follow-up 
period in eight of the 42 patients (19.0%). Patients in whom LV dysfunction recurred had 
discontinued neuro-hormonal blocker medication (62.5% versus 5.9%, P<0.05)(59). Cardiac 
ultrastructural changes, like interstitial fibrosis, can be risk factor for recurrent HF.  
Studies are needed to define what kind of neuro-hormonal blockade should be 
maintained after recovery of LV function. 
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4- CLINICAL INVESTIGATION AT HEART FAILURE AND TRANSPLANT 
CLINIC 
Previous clinical studies performed at the HF and Transplant Clinic of the Cardiology 
Department of Centro Hospitalar São João provided the background of the present 
investigation.  
The most important determinants of the improvement in the prognosis of DCM 
observed over the past years were: 1) the implementation of familial screening programs for 
DCM that have enabled earlier diagnosis; 2) the systematic implementation of evidence based 
medical and device therapies that promote LVRR.  
We verified a change in prognosis in the last 15 years. In a group of 219 patients with 
DCM of non-ischemic aetiology (about 80%), with mean LVEF of 24 ± 9%; NYHA class II or 
III, the survival of the 135 patients admitted before 1996 was lower than that of patients 
admitted later, coinciding with the beginning of the prescription of ß-blockers and 
mineralocorticoid antagonists, with no difference between the use of ACEI (156). 
In another study, patients with alcohol-related DCM (157), recovery occurred in 36% 
of 45 patients. Those who improved LV ejection fraction were more frequently abstinent (75% 
vs 28%, p <0.01), were in NYHA class I or II at the end of follow-up (100% vs 69%, p = 0.02) 
and had better survival (100% at 5 years and 80% at 10 years vs 64% at 5 years and 32% 
at 10 years, p <0.01). Patients with non-abstinent alcoholic DCM had a higher mortality than 
those with abstinent alcoholic DCM and tended to have a worse prognosis than patients with 
idiopathic DCM. The predictors of death or transplantation in patients with alcoholic DCM were 
the absence of alcohol withdrawal and the lower use of β-blocker. The predictors of death or 
transplantation in patients with idiopathic DCM were female gender, higher heart rate, lower 
body mass index, and lower β-blocker use (158) (Full text at Appendix I, published only in 
abstract form). 
In a retrospective study including 62 patients with idiopathic DCM, a significant 
improvement of LVEF occurred in 11 (18%) patients. Patients in whom LVRR occurred were 
younger at the time of diagnosis, had a lower heart rate and had lower diastolic diameters 
than those in whom it did not (159).    
It has been postulated that patients with non-ischemic cardiomyopathy are more likely 
to recover from LV dysfunction. In those patients, there is a pronounced adrenergic activation 
for an equivalent degree of myocardial dysfunction, but with a higher viable (non-necrotic) 
myocardium. A marked reduction in sympathetic activity appears to reduce mortality. The 
magnitude of heart rate reduction, rather than its baseline level, appears to be associated with 
a higher increase in LVEF (160). To corroborate this, we evaluated the effects of β-blockers on 
the recovery of LVEF in 30 patients (161) with DCM, a group (A) evaluated before and after 
carvedilol  up to the maximum tolerated dose, and a group Control (B) patients with HF and 
β-blocker intolerance. In group A, before and after the use of carvedilol, mean values of heart 
rate, ejection fraction, baroreceptor gain, HR variability in the high frequency domain were 
significantly lower (162) (163). 
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Another study of adrenergic activity with 123 I-MIBG in our HF clinic, in patients with 
familial DCM (164-166), showed that there is a lower value of cardiac/ medullary uptake rate 
and a higher rate of myocardial washout in patients With MCD phenotype relative to those 
without MCD phenotype. In some families with isolated LV abnormalities or with normal 
echocardiography (including 3 patients with reverse remodeling), high rates of myocardial 
washout were also found, suggesting that cardiac MIBG may reveal early changes in adrenergic 
activity. 
Regarding functional class and physical performance, the maximum VO2 value of the 
cardio-respiratory effort test (CPET) plays a fundamental role in the prognosis of HF patients. 
In a study (167), new variables of the cardio-respiratory effort test in dilated cardiomyopathy 
were studied, because the peak VO2 can be underestimated if the test is submaximal, common 
in the patient with HF. In 83 consecutive days with MCD, the predictive parameters of death 
or transplantation were VO2 peak, VO2 lean IMC> 30, dVE/ VCO2, dVE /VCO2 /VO2p, O2 pulse 
(%), circulatory power, percentage of VO2 at anaerobic threshold (AT), peak O2 consumption 
(POUE) efficiency and POUE in AT. The POUE and POUE in the LA were the parameters that 
showed greater protective effect, they represent the relationship between minute ventilation 
and oxygen uptake during exercise and incorporate cardiovascular and pulmonary factors, 
being relatively insensitive to the duration of exercise. 
Finally, to establish the prognosis of HF, peak VO2 and other prognostic scores such 
as the Heart Failure Survival Score (HFSS) have extensively studied. However, this score was 
validated in an era in which patients were not treated with β-blockers or with CRT/ICD. In our 
population (168) we sought to validate the current prognostic value of HFSS in 70 patients 
and to study other prognostic variables. The HFSS contributed to risk stratification, the use of 
β- blockers did not modify survival in the high risk and low risk groups of HFSS, but improved 
survival in the medium risk group: 100% at 1 year, 78% at 5 years, 65% at 10 years. Device 
use (27% of cases) was not significantly associated with improved survival. In addition to the 
parameters obtained for the calculation of HFSS, the predictors of death or urgent 
transplantation were the presence of elevated jugular venous pressure, S3 presence, right 
ventricular dysfunction, larger left atrial size, greater LVDD, greater LV mass index, higher 
PSAP and higher BNP. It is concluded that the addition of clinical/ hemodynamic parameters, 
parameters of ventricular and atrial remodeling, right ventricular function and BNP value may 
improve the efficacy of established prognostic scores.
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AIMS 
- Although several reviews have summarized the changes that occur at the cellular, 
molecular, and anatomic level during cardiac remodeling, fewer studies have focused 
on the factors that allow the heart to revert to normal LV size and shape (i.e., reverse 
remodeling). 
- Clarifying the mechanisms of reverse remodeling leading to sustained functional 
myocardial recovery will have a dual benefit: (a) it will enable changes in the 
therapeutic strategy by modifying the duration and intensity of treatment, aiming to 
promote myocardial recovery and (b) it will allow to identify reliable predictors of 
recovery. 
- The great majority of clinical reports on myocardial recovery found in the literature 
refer to cases occurring after transient injury (e.g., viral infection, inflammation, toxic 
injury) rather than after long-standing and/or permanent injury (e.g., myocardial 
infarction, genetic abnormalities). This is consistent with the view that the ability of 
the heart to “recover” is related to the injury nature and to the extent of the 
subsequent myocardial damage. Therefore, in this prospective study we aimed to 
evaluate recovery of left ventricular function and the reversal of ventricular remodeling 
in patients with more long-standing Heart Failure, i.e., patients with chronic Idiopathic 
Dilated Cardiomyopathy (DCM), after optimized medical therapy.  
- The predictors of left ventricular reverse remodeling (LVRR) in response to a specific 
therapeutic strategy need to be defined. In our population we evaluated the prevalence 
of LVRR, and the clinical, echocardiographic, biomarker, cardiopulmonary stress test 
(CEPT) predictors of the occurrence of LVRR. We included cardiac MRI in the evaluation 
protocol. This exam may indirectly assess contractile reserve, which may be inversely 
proportional to the extent of myocardial fibrosis.  
- In previous clinical trials most, but not all, interventions producing LV reverse 
remodeling translated into a beneficial effect on survival.  A secondary aim of our 
research was to evaluate the impact of reverse remodeling on prognosis in the setting 
of Idiopathic DCM.  
- Cardiomyocyte shortening improvement alone cannot provide a normal LVEF. Only 
appropriate LV shape (ellipsoid) and orientation of the myocardial fibres in a helicoidal 
or spiral form can achieve this goal. Non-contractile myocardial components contribute 
to the appropriate spatial orientation and the mechanical stability of cardiomyocytes 
and are essential for the maintenance of a normal LVEF.  
- Myocardial deformational parameters remain incompletely characterized in patients 
with DCM. LVEF does not correlate with patient symptoms, a normal LVEF does not 
exclude nor imply diastolic dysfunction, and LVEF cannot be used as a substitute for 
cardiac output. The changes in LV myocardial fibre length and thickness (myocardial 
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deformation or strain), which are fundamental component of LV dynamics, can be 
assessed with speckle tracking echocardiography. Therefore, we aim to evaluate 
detailed echocardiographic parameters in patients with DCM, during LVRR.  
- Cardiac extracellular matrix (ECM) is a dynamic structure and its turnover depends on 
a fine balance between matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs). The ECM plays an important role in the distribution of 
mechanical forces throughout the heart and, thus, it is crucial for maintenance of 
normal ventricular pump function (169). The deformation of the myocardial matrix 
during systole results in storage of mechanical energy, turning into a rapid untwist and 
recoil, generating diastolic suction that is important for early rapid filing of the LV.   
 
- The biochemical, structural, and functional roles of ECM changes remain the most 
poorly understood aspect of heart remodeling and reverse remodeling. As a final 
purpose, we evaluated emerging biomarkers in LVRR, mostly markers of ECM 
remodeling. We also measured others circulatory molecules related to biological 
pathways involved in HF, such as markers of neuro-hormonal blockade, inflammation 
and apoptosis. 
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    METHODS                                                                           
1. Inclusion criteria 
a) All patients included into this study had a diagnosis of idiopathic DCM defined by a left   
 ventricular ejection fraction (LVEF) < 40%, left ventricular diastolic diameter (LVDD) 
 > 33 mm/m2 in men or > 32 mm/m2 in women). 
b) All were followed at the HF and Transplant Clinic of Cardiology Department, were above 
 18 and were included consecutively. 
c) All patients had the diagnosis established between 2 to 3 years before inclusion and had 
 with two initial values of LVEF of <0.40 more than one year apart one from each other. 
d) In all cases the plausible etiology was unknown. 
 
2. Exclusion criteria 
 a) We excluded patients with left ventricular dilatation and dysfunction due to coronary   
 artery disease defined by the presence of one of the following: history of myocardial 
 infarction or angina pectoris, the presence of more than 50% diameter narrowing in 
 any of the major coronary arteries or their branches, or myocardial perfusion 
 abnormalities detected by SPECT or cardiac MRI.  
b)  We also excluded patients with other causes of DCM, such as: history of moderate or 
 severe hypertension; diabetes mellitus with end-organ damage or on insulin therapy, 
 primary mitral or aortic valvular disease of at least moderate degree; heavy alcohol 
 consumption (>100 g/day), chemotherapy-induced left ventricular dysfunction and 
 peripartum cardiomyopathy.  
c)   Patients with a history of uncontrolled atrial and ventricular arrhythmias were excluded. 
      d)  We excluded patients with acute HF with a positive biopsy for acute myocarditis, or 
 with a positive serology for acute phase of bacterial or viral infection, or with a cardiac 
 MRI compatible with acute myocarditis. 
      d)  We excluded patients with atrial fibrillation in a latter cohort, since it could introduce 
 errors in the assessment of LVEF. 
 
3. Definition of Left ventricular reverse remodeling 
In this study, left ventricular reverse remodeling (LVRR) was defined by the 
 simultaneous presence of the following conditions: 
 a) the occurrence during follow-up of an absolute LVEF increase ≥ 10 percentage units 
 (for instance a LVEF increase from 30% to 40%) comparing to baseline. This had to 
 be observed in at least two consecutive echocardiograms separated by more than 6 
 months,  
b) a concomitant decrease in LVDD, 
c) the increase in LVEF occurred in the absence of CRT or mechanical ventricular 
 assistance. 
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4.  Assessment of remodeling 
Two dimensional-echocardiography using the Simpson’s rule is considered the current 
 standard for LVEF and was the imaging method we used to evaluate the changes in 
 LVEF in our patients. Similarly, changes in LV volumes were assessed by 2D-
 echocardiography. 
Geometric abnormalities leading to loss of cardiomyocyte orientation underlie the 
 decrease of LVEF in eccentric hypertrophy (171). So, we measured LV sphericity index 
 which is a major determinant of LV twist and consequently of LVEF. 
 
We also assessed other important echocardiographic parameters:  
• Degree of mitral and tricuspid regurgitation by Doppler, 
• Pulmonary artery systolic pressure (PSAP), 
• Left ventricular mass,  
• Early diastolic (E) and atrial (A) wave velocities, E/A ratio, 
• E-wave deceleration time, spectral pulsed-wave Doppler–derived early 
diastolic velocity (e´) and  E/e´ratio,  
• Left ventricular myocardial performance index (LV Tei index), 
• Right myocardial performance index (RV Tei index),  
• Circumferential strain rates - assessed from basal, mid, and apical LV short-
axis views, 
• Longitudinal strain rate - assessed from the basal, mid, and apical levels in 
apical four-chamber, two-chamber, and long-axis views.  
 
5.  Baseline evaluation 
Baseline evaluation consisted of: 
 
- History and physical examination. 
- Electrocardiogram, 24-hour EKG. 
- General blood chemistry. 
- Transthoracic 2D-echocardiogram. 
- Cardiopulmonary stress test (CPET) with the determination of peak VO2, dVE/VCO2, 
dVE/VCO2/VO2p, O2 pulse (%), circulatory power, percentage of VO2 at anaerobic 
threshold (AT), peak O2 consumption (POUE) efficiency and POUE in AT, 
- Determination of Heart Failure Survival Score (HFSS). 
 
- Measurement of serum biomarkers: 
 
- Available biomarkers, reflective of diverse biological pathways in HF: 
• Adrenalin, noradrenalin (neurohormonal activation) 
• Plasma renin, aldosterone (neurohormonal activation) 
• B-type natriuretic peptide (BNP) (neurohormonal activation) 
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• High-sensitivity C-reactive protein (hsCRP) (inflammation) 
• Cancer antigen CA-125 (inflammation) 
• Uric acid and Lp(a) (oxidative stress) 
• Creatinine and cystatin C (renal function) 
• 25-OH-vitamin D (extracellular remodeling). 
 
- Novel biomarkers: 
• Markers of ECM remodeling:  
• Matrix metalloproteinase-3 (MMP-3) 
• Tissue inhibitor of matrix metalloproteinase- 2 (TIMP-2) 
• Protein ST2 (receptor for interleukin 33)  
• Galectin-3 
▪  Markers of inflammation: 
• Soluble TNF receptor I/TNFRSF1A (sTNF-R1iii)  
• Marker of apoptosis: 
• Growth-differentiation factor 15 (GDF-15). 
 
- Cardiac MRI, with quantification of the extent of LGE, quantified by the number of 
segments affected. 
 
 
6. Follow-up 
During follow-up, the patients were managed according to the European Society of 
Cardiology Heart Failure Guidelines and the maximal tolerated doses of the disease modifying 
drugs were administered.  
2D-echocardiograms were performed every 3 to 6-months and the occurrence of LVRR 
was assessed according to the above definition. 
Patients who received a CRT were considered to have no LVRR, so we analyzed the last 
echocardiographic data before the implantation of the device. 
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1. Prevalence, predictors and prognosis of reverse ventricular 
remodeling in idiopathic dilated cardiomyopathy 
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2. Left ventricular reverse remodeling in dilated cardiomyopathy: 
maintained subclinical myocardial systolic and diastolic dysfunction 
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3. Role of biomarkers in dilated cardiomyopathy- evaluation of 
clinical severity and reverse remodeling 
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4.   Profile of biomarkers of extracellular matrix, inflammation and 
apoptosis in left ventricular reverse remodeling 
 
Sandra Amorim; Inês Falcão-Pires; Marta Oliveira; João Rodrigues; Manuel Campelo; Brenda Moura; Filipe 
Macedo; Adelino F. Leite-Moreira, J Silva-Cardoso; M Júlia Maciel 
 
Under revision  
 
Acronyms and abbreviations: BSA: body surface area; DCM: dilated cardiomyopathy; LAVi: left atrial volume/BSA; LBBB: left bundle branch 
block; LVEF: left ventricular ejection fraction; LVDD: left ventricular end-diastolic diameter; LVDDi: left ventricular end-diastolic 
diameter/BSA; LVDV: left ventricular end-diastolic volume; LVDV: left ventricular end-diastolic volume/BSA; LVRR: left ventricular reverse 
remodelling; PASP: pulmonary artery systolic pressure; MR: mitral regurgitation 
 
INTRODUCTION 
Dilated cardiomyopathy (DCM) represents a common cardiomyopathy leading to heart failure (HF) and 
has an estimated prevalence of 1:2500 (1). In DCM, myocardial remodeling is characterized by ventricles 
enlargement, wall thinning, fibrosis as well as hypertrophy, slippage and loss of cardiomyocytes with 
subsequent systolic dysfunction (2). Treatment of DCM is essentially the treatment of chronic heart failure 
(HF), i.e., optimal pharmacological and/or resynchronization therapy, aiming for left ventricular (LV) 
reverse remodeling (LVRR). Indeed, LVRR, defined as a reduction in LV size with an improvement in 
systolic function, is a marker of a favourable prognosis in individuals with recent-onset DCM (3). 
ABSTRACT 
 
Background: Limited data exists regarding the usefulness of novel biomarkers to predict left ventricular 
(LV) reverse remodeling (LVRR) in dilated cardiomyopathy (DCM). We aim to evaluate the potential of 
emerging biomarkers in LVRR. 
Methods: We included 50 DCM patients with reduced LV ejection fraction (LVEF< 40%, 59±10 years, 
56% males). We assessed LVRR (an increase>10 U of LVEF) and measured levels of markers of 
extracellular matrix (MMP-3, TIMP-2, ST2, Galectin-3) and HF (BNP, GDF-15, sTNF RI, CA 125), at 
baseline and 41.2±23.4 months after. 
Results: LVRR occurred in 40% of patients within 17.6±15.6 months after pharmacological (n=17) and 
resynchronization therapy (n=3).  Patients with pharmacological LVRR had younger age (60.6±8.8 vs 
54.7±10.8, p=0.04), smaller LVDDi (mm/m2) (35.2±4.1 vs 32.3±4.8, p=0.03) and lower baseline 
galectin-3 (5.61±2.98 vs 8.68±4.35ng/ml, p=0.03). There was a significant decrease in BNP; but most 
biomarkers, particularly GDF-15 and MMP-3 (1140.01±928.45 vs 808.35±416.66 pg/ml;p=0.07; 
10.1±6.0 vs 6.1±3.0 ng/ml;p<0.01), continued to rise, despite medical therapy, even in patients with 
LVRR. 
BNP correlated directly with LVDDi (r=0.49), LVDV (r=0.51), PSAP (r=0.43), E/e´ (r=0,31); correlated 
inversely with LVEF (r=-0.50) and e´velocity (r=-0.32) (p<0.05).  CA 125 correlated with LAVi (r=0,46), 
E/A ratio (r=0,60) and PASP (r=0,49) (p<0.05).  GDF-15 correlated with E/e' (r=0.32, p=0.01); TIMP-
2 correlated with LVDVi (r=0.31, p=0.01), LAVi (r=0.28, p=0.02) and sphericity index (r=-0.29, 
p=0.02).  
Conclusions: Lower values of galectin-3 were associated with LVRR and correlations were found between 
biomarkers and echocardiographic parameters of LV remodeling, supporting the multidirectional 
pathway of remodeling in HF that involves cytokines, ECM activation and apoptosis. Despite LV systolic 
recovery, there is persistent diastolic disfunction, matrix fibrosis activation, apoptosis and inflammatory 
activity. 
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Currently, limited data exists regarding the utility of biomarkers to predict LVRR in DCM. So far, 
some studies have described potential biomarkers of reverse remodeling in several clinical contexts, but 
none were able to monitor LVRR progression or prognosis (4-7). Biomarkers of matrix remodeling and 
inflammation have emerged as potential preclinical indicators to identify individuals at risk of developing 
clinical HF (5, 8-10). Because LV remodeling seems to involve different pathophysiologic pathways, a 
multimarker panel meeting these requirements should help to refine risk stratification. 
High-risk patients prone to LV remodeling could thus receive more aggressive therapy and more 
frequent follow-up. Recent evidence supported the utility of biomarkers in adjusting anti-remodeling 
treatments for specific groups of patients (11). Galectin-3 is a member of the galectin family that binds b-
galactosides. In the failing heart, it is produced by macrophages and cardiac fibroblasts, an increase 
ofGalectin-3 promotes cardiac fibroblast proliferation, collagen deposition and ventricular dysfunction (10). 
Overexpression of matrix metalloproteinases (MMP)s may play an important role in ventricular 
remodelling, MMP-3 is important because of its ability to degrade a wide range of ECM components and to 
activate latent MMPs (12, 13). Tissue inhibitor of matrix metalloproteinases (TIMP)s have growth-
promoting properties, stimulate fibroblasts differentiation and displays endogenous independent 
properties, promoting angiogenesis, regulating apoptosis, and amplifying inflammation (14, 15). ST2 is a 
member of the interleukin 1 receptor family and exists in two forms, a transmembrane receptor (ST2L) 
and a soluble decoy receptor (ST2). The ligand of ST2L is interleukin 33, which is involved in reducing 
fibrosis and hypertrophy in mechanically strained tissues. Excess soluble ST2 leads to cardiac fibrosis and 
ventricular dysfunction (16). Growth-differentiation factor 15 (GDF-15) is a distant member of the 
transforming growth factor-β cytokine superfamily and appears to be involved in the regulation of cell 
differentiation and tissue repair with possible anti-apoptotic and antihypertrophic effects and closely linked 
with tissue remodelling (17). Soluble TNF receptor TNFR1 has proapoptotic effects—facilitated cardiac 
remodeling and apoptosis in cardiomyocytes, while stimulation of TNFR2 has an antiapoptotic effect and 
their blood levels are elevated in patients with severe HF (18). 
The aim of our study was to establish novel biomarkers of LVRR in the context of DCM. In this 
work, we evaluated the profile of emerging biomarkers in predicting LVRR, after optimal pharmacological 
or resynchronization therapy, in a cohort of ambulatory DCM patients. 
We measured circulatory molecules related to biological pathways involved in HF: i) Galectin-3, 
MMP-3, TIMP-2, protein ST2 (ECM remodeling); ii) GDF- 15 (apoptosis), ii) sTNF-R1 and carbohydrate 
antigen 125 (inflammation); iv) BNP (myocardial overload). 
METHODS 
 We included consecutive adult idiopathic DCM patients followed in a HF outpatient clinic, recruited 
from January 2011 to December 2014 in a tertiary care centre, with a diagnosis of less than 2 - 3 years 
duration. Patients must have had two initial values of LVEF lower than 40%, more than one year apart, to 
exclude reversible causes, like myocarditis. All patients were in sinus rhythm and patients with history of 
uncontrolled atrial and ventricular arrhythmias were excluded. December 2015 was considered the final 
follow-up date. We excluded DCM patients with secondary aetiologies, such as: 1) history of myocardial 
infarction or angina, with ischemia or significant coronary disease assessed by coronary angiography; 2) 
history of moderate to severe hypertension; 3) primary moderate-severe mitral or aortic valvular disease; 
4) heavy alcohol use (>100 g/ day); 5) chemotherapy-induced and peripartum cardiomyopathy; 6) acute 
HF with positive biopsy for myocarditis or with positive serology for acute phase of bacterial or viral 
infection. 
At baseline, patients underwent clinical assessment, EKG, transthoracic echocardiogram and 
blood collection for analytic measurements. Patients were managed according to current clinical practice 
guidelines (19) and clinicians adjusted the recommended target doses for all therapies. During the follow 
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up, periodic clinical evaluation, laboratory measurements and echocardiogram on a 3 to 6 months’ basis 
were performed. All patients gave written informed consent. This study was performed in accordance with 
the recommendations set by the Declaration of Helsinki (20) and approved by the local  Ethics Committee. 
Definition of LVRR 
LVRR was defined as an absolute increase of at least 10 units of LVEF in two subsequent 
echocardiograms, more than six months apart, concomitant with a decrease in diastolic left ventricular 
diastolic diameter (LVDD), LV systolic and diastolic volumes and LV mass, without worsening of mitral 
regurgitation (MR), if present. 
Transthoracic echocardiography protocol 
Transthoracic echocardiography was performed at baseline and during follow-up procedures using 
a commercially available echocardiographic system (General Electric Vivid 7.0) with a 2.5-MHz transducer. 
The chamber quantification parameters were measured according to the professional standards defined 
by the American Society of Echocardiography and the European Association of Echocardiography (21); 
LVEF (%) was calculated by Simpson’s biplane method; degree of mitral and tricuspid regurgitation by 
Doppler, scored on a scale from 0 to 4; pulmonary artery systolic pressure (PASP) was calculated by 
tricuspid velocities. LV mass was calculated using the formula proposed by Devereux et al (22). LV 
sphericity index was calculated as the ratio of dimensions of long axis view and minor axis view. The early 
diastolic (E) and atrial (A) wave velocities, the E/A ratio, and the E-wave deceleration time were measured 
using pulsed wave Doppler recording from the apical four-chamber view. Spectral pulsed-wave Doppler–
derived early diastolic velocity (e´) was obtained from the septal mitral annulus, and the E/e’ ratio was 
calculated to obtain an estimate of LV filling pressure. The myocardial performance or Tei index was 
retrieved from the mitral flow pattern and calculated by the formula = (IVCT + IVRT)/ET, were IVCT is the 
isovolumic contraction time, IVRT corresponds to the isovolumic relaxation time and ET to ejection time. 
LV Tei index was measured at the septal and lateral sites of the mitral annulus and RV Tei index was 
determined as the difference in duration between tricuspid regurgitation and pulmonary ejection divided 
by pulmonary ejection duration. All data were digitally stored, and off-line double-blinded data analysis 
was performed by two echocardiography specialists. To assess the variability in interpretation, all 
echocardiograms were analysed independently by two echocardiography specialists, blinded to the study. 
The reproducibility of the measurements was calculated on the basis of standard error of the estimate; 
both interobserver and intraobserver variations were ≤5% for follow-up LVEF and LV volumes. 
Biomarker´s assessment 
All biomarkers were measured from plasma obtained at the time of study entry and at the end of 
follow-up. At baseline and follow-up venous blood samples were collected to ethylenediamine-tetra-acetic 
acid-containing tubes. After a 30 min-rest, blood samples were centrifuged at 5000 rpm for 15 min at 4°C, 
and plasma was collected and frozen at -80°C until analysis. BNP was measured by chemiluminescent 
immunoassay (Abbott). CA 125 was determined by chemiluminescence (Abbott). Plasma Soluble ST2 was 
quantified using a human IL-1 R4/ST2 enzyme-linked immunosorbent assay (R&D Systems, Abingdon, 
United Kingdom). Plasma MMP-3, TIMP-2, Galectin-3, GDF-15 and sTNF-R1 were also quantified by human 
enzyme linked immunosorbent assays (R&D Systems, Abingdon, United Kingdom) according to the 
manufacture instructions. Score ST2-R2, defined by Lupon et al (2), was not calculated due to differences 
between our immunoassay and the assay that they used in their study. 
Statistical analysis 
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All values are reported as mean ± SD, median [interquartile range] or as percentages according 
to type of data. Differences between categorical data were assessed using X2 test. Groups were compared 
by two-way repeated measures ANOVA for baseline and follow-up analysis. Sequential comparisons within 
the same individual were assessed by a paired Student t test, Kolmogorov-Smirnov or Mann-Witney test 
after confirming normality and homogeneity of variance with Shapiro-Wilk and F tests, respectively. 
Bonferroni-adjusted t tests were used subsequent for multiple comparisons after repeated measure 
ANOVA, two-tailed P<0.05 was considered to indicate statistical significance. The correlation between 
plasma markers analysed and echocardiography parameters was analysed using the Pearson´s correlation 
test. Non-normally distributed continuous variables were log-transformed. Statistical analysis was 
performed with SPSS 23.0 statistical package (SPSS Inc., Chicago, IL, USA). 
RESULTS 
Population characteristics 
We included 50 consecutive patients with DCM, 56% males, aged 59±10 years-old, mostly in 
NYHA class II (62%), followed for 39±22 months. On EKG, 66% patients had LBBB, all were in sinus 
rhythm. Mean left ventricular EF was 25.4±9.8%, LVDD was 62.4±7.4mm, LVDDi was 34.2±4.5mm/m2 
and 34% had MR grade > II/IV. At baseline, 76% of patients were already treated with angiotensin-
converting enzyme inhibitors (ACEI)/ angiotensin II receptor blockers (ARB), and 62% with β-blockers 
and 14% with mineralocorticoid receptor antagonists. At the end of the follow-up, 94% were on medication 
with ACEI/ ARB, 98% on β- blockers and 60% on mineralocorticoid receptor antagonists. Optimal 
recommended doses of ACEI/ARB were reached in 42% and optimal doses of β-blockers were reached in 
48%. During follow-up 22% of patients were hospitalized for HF worsening, 4% died (n=2) and 40% 
received an implantable cardiac defibrillator (ICD). At the end of the follow-up, 15 patients (30%) had 
LBBB and a LVEF ≤35%, but only 8% received a cardiac resynchronization therapy plus ICD (CRT-D). The 
remaining patients didn´t implant the CRT because of: NYHA class I, technical problems, refusal of the 
device, transient LVEF recovery, presence of LV diverticulum and old age. Predictors of left ventricular 
reverse remodeling (LVRR) LVRR, defined as an increase of LVEF more than 10 units, occurred in 20 
patients (40%) within 17.6±15.6 months. In 17 patients, it occurred after pharmacological treatment and 
in 3 patients (with no pharmacological LVRR) it occurred after CRT-D implantation. The baseline LVEF of 
patients who recovered LV function after medical therapy was like those who did not recover (24.9±9.0% 
vs 26.5±11.2%, p=0.58). We found that patients who recovered LV function had: younger age (60.6±8.8 
vs 54.7±10.8, p=0.04), smaller LVDDi (mm/m2) (35.2±4.1 vs 32.3±4.8, p=0.03). Patients that had 
pharmacological LVRR had lower basal levels of galectin-3 (5.61±2.98 vs 8.68±4.35 ng/ml, p=0.03). We 
did not find other baseline clinical and echocardiographic factors that predicted LVRR. Further details are 
described in Table 1.  
Patients with LVRR had a final EF of 48.9 ± 7.9% (Δ LV EF of 22.4%), and had a significant 
decrease (p < 0.05) (see Figure 1) in: LVDD (53.5 ± 6.7 mm; Δ LVDD of ± 7.2 mm), LVDDi (28.3± 3.0 
mm/m2), LVDV (145.5 ± 32.7 ml), LVSV (73.6 ± 25.2 ml), LVMi (122.3±32.2 g/m2); and an increase (p 
< 0.05) in sphericity index (1.57 ±0.18) and only 5.9 patients (n=1) had a final MR ≥ grade II/IV. 
Controversially, in patients with reverse remodelled DCM, measures of diastolic function as LAVi, e′ velocity 
and E/e′ ratio, LV Tei index and RV Tei index were not significantly different from baseline. See Table 2 
for further details. 
 
Biomarker levels 
BNP decreased significantly at the end of follow-up in patients who recovered LVEF (81.3±189.4 
vs 20.6±54.5 pg/ml, p<0.05) but also in patients who didn´t recovered LVEF (171.2±530.1 vs 81.3±182.2 
pg/ml, p<0.01). Paired analysis of novel biomarkers was only considered in 35 patients: 2 patients died 
suddenly and didn´t collect the final sample, the other patients had technical problems in collecting 
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samples or didn´t collect at the time of echocardiogram. Figure 2 and Table 3. displays the differences in 
the levels of plasma biomarkers at the baseline and at the end of follow-up, in patients with and without 
LVRR.  
Mean baseline levels of galentin-3 were 7.81 ±3.66 ng/ml. Patients that had pharmacological 
LVRR had lower baseline levels of galectin-3 (vide supra). Although galectin-3 values seem to decrease 
during follow-up, it was not statistically different in patients with or without LVRR (Figure 2). At the 
beginning of follow-up, levels of MMP-3 were 8.05 ±5.11 ng/ml and all patients with levels more than 8 
ng/ml were male. We found that MMP-3 significantly increased during follow-up both in patients with and 
without LVRR (No LVRR: 6.52±3.42 ng/ml vs 10.58±7.31 ng/ml, p=0.01; LVRR: 5.48±2.28 ng/ml vs 
9.45±4.06 ng/ml, p<0.01), Baseline TIMP-2 levels were 87.92 ± 31.01 ng/ml and was not associated with 
LVRR. There also no significant changes during follow-up both in patients with LVRR (Figure 2). Baseline 
levels of ST2 were 17.79±8.1 ng/ml, were not associated with LVRR (18.56±6.65 vs 18.40±7.03, p=0.25) 
and there weren´t no significant changes during follow-up. In the case of GDF-15 (mean 1048.10±692.08 
pg/ml) we found a tendency for an increase only in patients who recovered LVEF (1140.01±928.45 pg/ml 
vs 808.35±416.66 pg/ml; p=0.07). sTNF RI at baseline was 1105.86±414.87 pg/ml, we found a tendency 
for an increase over time, in the overall population (baseline: 10.73±3.32 vs final 11.62 ±5.00 ng/ml, 
p=0.057. 
 
Correlations between biomarkers and echocardiographic parameters 
However, some of the biomarkers showed important correlation with echocardiographic 
parameters of ventricular remodeling (Figures 3 and 4). Such is the case of BNP that correlated with BNP 
correlated directly with LVDD (r=0.49), LVDV (r=0.51), PASP (r=0.43), E/e´ (r=0,31); and was inversely 
correlated to LVEF (r=-0.50) and e´velocity (r=-0.32) (p<0.05). CA 125 positively correlated with LAVi 
(r=0,46), E/A ratio (r=0,60) and PSAP (r=0,49) (p<0.05). GDF-15 correlated with E/e' (r=0.32, p=0.01); 
GDF-15 positively correlated with E/e’ ratio (r=0.32, p=0.01). TIMP-2 was weakly positively correlated 
with LVDVi (r=0.31, p=0.01), LAVi (r=0.28, p=0.02) and inversely with sphericity index (r=-0.29, 
p=0.02). MMP-3 had a weak positive correlation with LVEF (r=0.35, p=0.01). Controversially, ST2 had a 
weak negative correlation with LAVi (r=-0.26, 0=0.04) and a weak positive correlation with sphericity 
index (r=0.28, p=0.02). Moreover, certain plasma markers correlated with each other. Significant 
correlations were found between BNP and CA 125 (r= 0.64, p<0.01). CA 125 was positively correlated 
with GDF-15 (r=0.34, p=0.04) and with TIMP-2 (r=0.38, 0=0.02). sTNF RI was also correlated with TIMP-
2 (r=0.34, p=0.01), with GDF-15 (0.50, p<0.01), Galectin-3 (r=0.31, p=0.01) and with MMP-2 (r=0.55, 
p=0.01). Lastly, GDF- 15 correlated with TIMP-2 (r=0.31, p=0.01). 
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 Table 1. Baseline clinical, echocardiographic, biochemical characteristics and therapy of dilated 
 cardiomyopathy patients separated according to the presence or absence of pharmacological 
 left ventricular reverse remodeling (LVRR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 ICD/CRT: implantable cardiac defibrillator/ cardiac resynchronization therapy; LAVi: left atrium volume/body 
 surface area; LBBB: left bundle branch block; LVDD: left ventricular end-diastolic diameter; LVDDi: left 
 ventricular end-diastolic diameter/body surface area;  LVDVi: Left ventricular diastolic volume/body surface 
 area; LVEF: left ventricular ejection fraction; LVMi: left ventricular mass/body surface area NYHA: New York 
 Heart Association; MR: mitral regurgitation; PASP: pulmonary artery systolic pressure;  
 
 
 
 
 
 
 
 
 
 
 
 
No LVRR  
(n=33) 
LVRR  
(n=17) 
p 
 
Age (years) 
Male sex (%) 
Mild Hypertension (%) 
Heart rate (bpm) 
Systolic blood pressure (mmHg) 
QRS duration (ms) 
LBBB (%) 
NYHA class I (%) 
NYHA class II (%) 
NYHA class III -IV (%) 
 
Biomarkers  
BNP (pg/ml)  (median ± IQR) 
CA 125 (U/ml) 
sTNF RI/TNFRSF1A (pg/ml) 
TIMP-2 (ng/ml) 
ST2 (ng/ml) 
MMP-3 (ng/ml) 
Galectin 3 (ng/ml) 
GDF-15 (pg/ml) 
 
Echocardiogram 
LVEF (%) 
LAVi (ml/m2) 
LVDD (mm) 
LVDDi (mm/m2) 
LVMi (g/m2) 
LVDVi (ml/m2) 
LV Tei index 
Mitral regurgitation ≥ grade II (%) 
PASP (mmHg) 
RV dimension (mm) 
RV Tei index 
RV S velocity (m/s) 
E/e´ 
E´velocity (m/s) 
 
Therapy    Basal /Final (%)  
ACEI /ARB  
Maximal dose ACEI/ARB 
β- blockers 
Maximal dose β-blockers 
Aldosterone antagonist   
Ivabradin 
Diuretics 
ICD 
CRT-D 
60.6±8.8 
54.5 
57.6 
77.7±14.9 
124.5±18.0 
140.6±27.7 
69.7 
27.3 
57.6 
12.5 
 
 
171.1±530.1 
32.7±76.6 
1140.98±314.00 
95.25±33.39 
18.40±7.03 
6.13±3.30 
8.68±4.35 
1048.77±556.95 
 
 
24.9±9.0 
70.3±26.3 
63.3±7.6 
35.2±4.1 
167.4±24.7 
111.6±30.0 
0.78±0.34 
36.4 
31.0±9.4 
26.5±2.8 
0.46±0.16 
0.13±0.02 
14.7±7.1 
0.07±0.03 
 
 
81.8/93.9 
18.2/42.4 
57.6/97.0 
6.1/42.4 
12.1/63.6 
0.0/6.1 
57.6/66.7 
0.0/45.5 
0.0/12.1 
54.7±10.8 
58.0 
58.8 
73.6±11.3 
123.4±21.7 
136.1±33.8 
58.8 
17.6 
70.6 
11.8 
 
 
81.3±198.4 
47.8±152.1 
958.47±341.04 
79.65±33.01 
18.56±6.65 
5.92±2.26 
5.61±2.98 
742.36±370.94 
 
 
26.5±11.2 
67.4±25.0 
60.7±6.9 
32.3±4.8 
161.5±35.2 
106.4±27.3 
0.82±0.37 
29.4 
29.6±7.8 
28.4±3.6 
0.52±0.32 
0.12±0.02 
11.9±5.2 
0.07±0.01 
 
 
64.7/94.1 
29.4/41.2 
70.6/100 
5.9/58.8 
17.6/52.9 
5.9/17.6 
47.1/64.7 
0.0/29.4 
0.0/0.0 
0.04 
0.77 
0.93 
0.98 
0.85 
0.13 
0.44 
0.45 
0.37 
0.94 
 
 
0.50 
0.65 
0.11 
0.19 
0.25 
0.84 
0.03 
0.09 
 
 
0.58 
0.47 
0.25 
0.03 
0.49 
0.57 
0.72 
0.62 
0.65 
0.06 
0.42 
0.56 
0.19 
0.86 
 
 
0.18/0.98 
0.36/0.93 
0.37/0.47 
0.98/0.27 
0.59/0.46 
0.98/0.20 
0.48/0.89 
…/0.27 
…./0.13 
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Table 2. Comparison basal and final echocardiography parameters in patients with LVRR 
 
LAVi: left atrium volume/body surface area; LVDD: left ventricular end-diastolic diameter; LVDDi: left ventricular end-
diastolic diameter/body surface area;  LVDVi: Left ventricular diastolic volume/body surface area; LVEF: left ventricular 
ejection fraction; LVMi: left ventricular mass/body surface area 
 
 
Figure 1. Echocardiographic measures of left ventricular reverse remodeling (LVRR)  
 
 
LAVi: left atrium volume/body surface area; LVDDi: left ventricular end-diastolic diameter/body surface area;  LVDVi: 
Left ventricular diastolic volume/body surface area; LVEF: left ventricular ejection fraction. 
 
 
 
 
 
 
 
 
n= 17 Basal Final p 
LVEF (%) 
LVDD (mm) 
LVDDi(mm/mm2) 
LVSD (mm) 
LVSVi(mm/mm2) 
LVMi (g) 
Sphericity index  
LVDV (ml) 
LVSV (ml) 
LV Tei index 
LAVi (ml/mm2) 
E/e´ratio 
e´velocity (cm/s) 
RV Tei índex 
26.5±11.2 
60.7±6.9 
32.3±4.8 
54.4±7.9 
25.9±3.5 
159.1±34.8 
1.44±0.22 
201.4±48.5 
152.4±55.9 
0.82±0.38 
35.6±14.4 
11.6±4.6 
6.7±1.5 
0.56±0.35 
48.9±7.9 
53.5±6.7 
28.3±3.0 
41.5±4.6 
20.5±0.6 
122.3±32.2 
1.57±0.18 
145.5±32.7 
73.6±25.2 
0.74±0.23 
28.8±3.8 
10.47±4.2 
7.7±2.2 
0.39±0.17 
<0.01 
0.01 
<0.01 
<0.01 
0.02 
0.01 
0.02 
<0.01 
<0.01 
0.45 
0.27 
0.49 
0.14 
0.13 
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Table 3. Baseline and follow-up biomarker data according to the presence or absence of left ventricular 
reverse remodeling (LVRR) 
 
 
* Included in this analysis 13 patients with LVRR after pharmacological treatment plus 3 patients with LVRR after CRT-D 
 
 
 
 
 
 
Figure 2. Change in biomarkers from beginning to the end of follow-up in patients with and without left 
ventricular reverse remodelling (LVRR). 
 
 
 
 
 
 
 
 
 No LVRR 
(n=19) 
LVRR 
(n=13+3) * 
 Baseline Follow-up p    Baseline Follow-up p 
 
BNP (pg/ml)  
sTNF RI (pg/ml) 
TIMP-2 (ng/ml) 
ST2 (ng/ml) 
MMP-3 (ng/ml) 
Galectin-3 (ng/ml) 
GDF-15 (pg/ml) 
 
413.8±641.4 
1097.6±283.2 
96.8±36.0 
16.91±6.11 
6.52±3.42 
8.48±4.38 
1041.6±570.4 
 
130.3±153.5 
1213.6±493.4 
91.0±27.0 
18.00±8.16 
10.58±7.31 
8.37±2.68 
1179.1±755.6 
 
0.04 
0.16 
0.64 
0.36 
0.01 
0.09 
0.31 
    
300.5±646.1 
988.4±329.4 
81.73±30.01 
17.80±7.98 
5.48±2.28 
6.42±3.65 
808.35±416.66 
 
37.9±32.16 
1097.4±518.0 
80.96±30.20 
18.49±10.51 
9.45±4.06 
7.73±3.70 
1140.01±928.45 
 
0.01 
0.22 
0.92 
0.78 
<0.01 
0.10 
0.07 
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Figure 3. Correlations between BNP and CA 125 and echocardiographic parameters 
 
 
 
 
Figure 4.  Correlations between GDF-15, TIMP-2, MMP-3 and echocardiographic parameters 
 
 
DISCUSSION 
 
After an initial injury to the myocardium, cardiac remodeling occurs, ultimately leading to left 
ventricular dysfunction and HF. Activation and proliferation of fibroblasts, which increase the synthesis of 
fibrillar collagen and activate the inflammatory response, play an important role (23). In our study, 
younger age, a smaller LVDDi and galectin-3 were the predictors of LVRR after pharmacotherapy, with 
lower levels being associated with a process of LVRR. Galectin-3 plays a role in this process, because it 
binds to ECM proteins and cell surface receptors (24). Lok et al. (10) found that patients whose LV volume 
decreased over time had significantly lower levels of galectin-3 at baseline. Experimental studies showed 
that inhibition of galectin-3 and aldosterone can reverse isoproterenol-induced left ventricular dysfunction 
in mice (25). This highlights the mechanistic link between the biological role of galectin-3 and cardiac 
fibrosis as well as its negative impact on cardiac structure and function. Controversially, plasma galectin-
r=0.35  p=0.01 r=0.32 p=0.01 r=0.31  p=0.01 
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3 did not change significantly there was no correlation between galectin-3 and echocardiographic 
measurements. This is consistent with studies in HF patients who failed to demonstrate any relationship 
between galectin-3 and LVEF (26). Weir et al (27) showed that plasma galectin-3 increased significantly 
over time and there was no correlation with LVEF or LV volumes on the baseline CMR scan, in patients 
with acute myocardial infarction (AMI) and LV dysfunction.  
In our population, MMP-3 significantly raised during follow-up and those changes occurred both 
in patients with or without LVRR. In the literature, there are conflicting results between levels of MMPs. 
One large study in patients with AMI and MMP-3 measured at different time points from admission, showed 
that higher levels were associated with LV dysfunction, adverse LV remodeling and prognosis (28). 
Morishita et al. (29) studied 25 patients with successful reperfusion after an AMI and 15 normal controls, 
demonstrated that MMP-2 decreased to a minimum value within one week after the AMI, and then 
increased until 6 months after the AMI, which was ascribed to myocardial matrix degradation and a 
prolonged inflammation. In our study, TIMP-2 was correlated positively with LVDDi, LAVi and negatively 
with sphericity index, showing an association with pathological remodeling in DCM. In a recent study by 
Trucco et al. (30) with 42 patients that implanted CRT, TIMP-1 was a powerful predictor of long-term 
mortality. Another study showed that ΔTIMP-2 correlated with ΔLVESVi and with ΔLVEDVi and TIMP-2 
levels, but started high and increased over time (31).  
GDF-15 levels increased during follow-up, with a marginal difference in favour of patients who 
recovered LVEF; although higher levels of GDF-15 correlated with worse diastolic function (increased E/e’). 
In the Val-HeFT study, GDF-15 levels increased over the course of 12 months in patients randomized to 
the placebo arm (8). Although our lack of statistical difference was probably due to a small sample, our 
results can indicate a potential role of GDF-15 to track functional recovery during reverse remodeling. 
Similarly to other studies (32-35), BNP correlated positively with LV dimensions, LV volumes, LAVi and 
E/e´ratio, and negatively with LVEF; it is not surprising since the greatest secretion of B-type peptides is 
from the LV, in response to myocardial stretch. Serum CA125 is a tumor marker widely used in patients 
with ovarian cancer (36) and increased serum CA 125 values have also been shown in HF patients, caused 
by activation of the cytokine pathway (37). Serum levels of CA125 obtained in 286 HF patients correlated 
with CHF severity (NYHA class, e´ velocity, right atrial pressure) and with short-term prognosis (38). In 
our sample, CA 125 correlated mainly with measures of diastolic dysfunction. Our study was limited by 
the small number of patients, so there may be correlation between biomarkers and the occurrence of LVRR 
which was obscured. Comparing the baseline values of biomarkers in patients with and without LVRR, 
almost all biomarkers in the group who recovered LVEF had lower values, but only the levels of galectin-
3 reached statistical significance. In the analysis of basal and final levels of biomarkers in our population, 
there was a significant decrease in BNP; but some biomarkers, particularly GDF-15 and MMP-3, continued 
to rise, despite HF therapy, even in patients with LVRR. We can speculate that the positive benefit on the 
myocyte cytoskeleton, in patients who recovered LVEF, goes beyond the aggravation of the other pathways 
or; despite ventricular reverse remodeling, there is persistent matrix fibrosis activation, apoptosis and 
inflammatory activity. Consistent to the last hypothesis are the results of The Penn Heart Failure Study, 
which included 1821 chronic HF patients (39). The HF-Recovered group was associated with a better event-
free survival than HF-reduced EF and HF preserved EF groups; but this group still had abnormal BNP, uric 
acid, ST2, and soluble fms-like tyrosine kinase-1 and continued to experience HF hospitalizations, 
suggesting persistent HF risk (39). In another study, the recurrence of LV dysfunction, in HF recovered 
patients, was significantly correlated with the discontinuation of heart failure drugs (40). Also, despite the 
improvement in LVEF the risk of sudden cardiac death is continues (albeit at a lower level) (41). We 
therefore conclude that those findings provide a rationale to continue background medical or device 
therapy for HF-Recovered patients. Although LVRR refers to change in LV systolic function, LV size, 
volumes and mass, it is better to call it a “functional improvement” rather than true LV recovery. This is 
consistent with our data that diastolic function and myocardial performance indexes in patients with 
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reverse-remodelled DCM maintain impaired. Even though several biomarkers showed significant 
correlations with echocardiographic parameters and between each other, it was only a weak to moderate 
relationship. However, we still think that changes at the ECM can have an impact on myocardial function 
and structure recovery in DCM patients and our results corroborate the hypothesis of a multidirectional 
pathway of activation in HF that involves cytokines, ECM activation and apoptosis. 
 
Study limitations 
This was an analysis of a small, single-centre study. Our patient selection and definition of LVRR 
was strict and this may have conditioned the results. Measurement of biomarkers in two blood samples 
and non-uniform clinical follow-up time intervals might have limited the evaluation of changes of 
biomarkers over time. Lastly, it is not possible to know whether medications commonly used for HF can 
affect concentrations of the biomarkers. 
 
CONCLUSIONS 
Lower baseline values of galectin-3 were associated with reversal of LV remodeling, suggesting 
that galectin-3 may have a negative impact on cardiac function and lower levels of this marker may be a 
predictor of LVRR in DCM patients. Significant correlations were found between the levels of biomarkers 
and echocardiographic parameters of LV remodeling, supporting the multidirectional pathway of 
remodeling in HF. 
Despite LV systolic recovery, there is persistent diastolic disfunction, matrix fibrosis activation, 
apoptosis and inflammatory activity. 
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5. Left ventricular mechanical reverse remodeling not followed by 
electrical reverse remodeling 
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1. DISCUSSION OF RESULTS                                                                       
 
1.1  Prevalence, predictors and prognosis of reverse ventricular remodeling 
in idiopathic dilated cardiomyopathy 
We studied the prevalence of LVRR in patients with Idiopathic DCM under optimized 
medical therapy, as well as it´s predicting factors and prognosis.  
A total of 113 DCM patients were followed for 7.1±5.6 years. LVRR occurred in 34.5% 
of our patients after an average follow-up of 22.6 months.  
On univariate analysis, the predictive factors for LVRR (p<0.05) were the presence of 
mild hypertension, atrial fibrillation, ECG criteria of left ventricular hypertrophy, shorter QRS 
duration, absence of left bundle branch block, higher haematocrit value, lower LV Diastolic 
Diameter index, higher peak oxygen uptake efficiency (VO2/log10[VE]), lower dVE/VCO2/VO2, 
treatment with ACEI)/ARB and the use of ACEI/ARB and β-blockers at maximal dosages. 
Multivariate regression analysis showed that the use of higher ACEI/ARB doses was 
independently associated with LVRR (OR: 0.32, 95% CI 0.11--0.92).  
LVRR was associated with an improvement in NYHA functional class, a decrease in BNP 
values and a much better prognosis as opposed to what observed in patients in whom LVRR 
did not occur. In a meta-analysis, by Kramer et al., including 118 clinical trials (n=89,687 
patients; median follow-up 17 months) survival was correlated with therapy-derived 
improvement on LVEF (r=0.51, p=0.001), LV Diastolic Volume (r=0.44, p=0.002), and LV 
Systolic Volume (r=0.48, p=0.002) (173). 
The prevalence and the predictors of reverse remodeling in patients with DCM is not 
well established since the various studies previously published are not homogeneous in terms 
of the definition of reverse remodeling, of the populations studied, of the treatment applied 
and of the duration of the follow-up (172). These studies included heterogeneous populations 
with a variable ratio of patients presenting dilated cardiomyopathy of recent onset or secondary 
to reversible causes such as viral myocarditis, or toxic insult (54, 56). These are patients a 
higher potential for LVRR, either because of resolved activity of underlying disease (as in the 
case of acute myocarditis) or because of the favorable effects of neuro-hormonal blockade. 
This was why we specifically studied a homogeneous population of patients with IDCM under 
optimized medical therapy and excluded those in which IDCM was of a recent onset (172). 
LVEF recovery and reverse remodeling were associated with the use of ACEI/ARB and 
β-blockers at maximal tolerated dosages. Experimental evidence suggests that β-blockers can 
increase the production of sarcoplasmic reticulum calcium ATPase mRNA and α-myosin heavy 
chain mRNA and decrease the synthesis of  β-myosin heavy chain mRNA (8); these changes 
translates  in an improved contractility and in recovery of the failing cardiac myocytes. 
Our results are consistent with the literature investigating the clinical variables 
associated with LVRR in DCM (174-176).  Cicoira et al (177) in 98 patients with IDCM, showed 
that LVRR tended to occur in patients with a shorter duration of symptoms, a worse NYHA 
class and history of hypertension.  In another study (178), LVRR was found in 89 (37%) of 
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242 patients with IDCM and the baseline predictors of LVRR were a higher systolic blood 
pressure and the absence of left bundle branch block. Binkley et al. (179) showed that patients 
experiencing LVEF recovery were younger and more frequently female, had a lower prevalence 
of diabetes and of  ischemic heart disease and a higher prevalence of hypertension, and had 
higher systolic blood pressure, lower serum creatinine level and shorter QRS interval.  
In DCM, LBBB may be either causative or secondary to the underlining disease. LBBB 
may in fact be the cause of non-ischemic cardiomyopathy and in selected patients its resolution 
through CRT has been associated with normalization of LV function. On the other hand, DCM 
is associated with ventricular rearrangements and conduction delays, ultimately leading to 
LBBB.  In our population, mean QRS duration of patients who did not recover LV function was 
130 ms and this finding is consistent with the recommendations for biventricular pacing.  
There is not a definite agreement in the literature regarding cardiac MRI late 
gadolinium enhancement (LGE) as a predictor of LVRR. Kubanek M et al. observed that in 
patients with recent-onset DCM (some of them with myocarditis)  low extent of LGE and high 
edema ratio on CMR imaging were the most powerful baseline predictors of LVRR (56). In a 
study of 97 patients with DCM, LVRR (increase in LVEF of 5%), neither baseline LVEF nor the 
presence of CMR-LGE (88 patients) predicted LVRR (180). In another sub-study of 66 DCM 
patients LGE was detected both in the patients who did not experience LVRR as well as in 
patients with late LVRR, although the extent of LGE enhancement was lower in patients who 
responded compared to the non-responders (181). In our study, we failed to demonstrate that 
the presence or the extent of LGE on cardiac MRI as a predictor of LVRR, but possibly this was 
due to the small sample of our population. 
In summary, in IDCM LVRR occurs in approximately one third of the patients under 
maximally tolerated medical therapy. A set of variables can discriminate patients in whom 
LVRR is likely to occur from those in whom it is not and who may require CRT therapy or more 
aggressive strategies, like heart transplantation. Current guidelines suggest that ICD/CRT 
should only be implanted after reassessment of LVEF following titration to maximally tolerated 
doses of medical therapy. Since, as above described, we may be able to discriminate patients 
that are likely to recover LVEF from those who are not, we may hypothesize that those with a 
more severe status, like those with LBBB, low systolic blood pressure, or larger left ventricular 
diameters, should implant an ICD/CRT at an earlier occasion, since it is relatively unlikely that 
they recover LV function only under medical therapy. 
 
1.2  Persistent subclinical myocardial systolic and diastolic dysfunction after 
left ventricular reverse remodeling in idiopathic dilated cardiomyopathy 
 LVEF is not the most precise indicator of remodeling, as other metrics, such as LV 
volumes and mass, relate more closely to prognosis and to the impact of therapy (170). The 
LVEF value depends closely and inversely on LVEDV. For the same stroke volume, LVEF will be 
greater if LVEDV is smaller and vice versa. Thus, LVEF is unable to predict the magnitude of 
stroke volume, which is the true indicator. However, LVEF give us a standardized care and 
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implement quality assurance, it is not a limitation, but a tool. In ongoing and planned HF trials, 
EF remains a fundamental criterion.  
Evaluating LV function strain rate imaging has a theoretic advantage over Doppler 
tissue imaging because it is relatively immune to cardiac translational motion and tethering 
(182). Several authors showed that in patients with HF global strain is a powerful predictor of 
cardiac events with a better accuracy than LVEF (183-185). Circumferential and longitudinal 
speckle-tracking strain rate analysis can be useful to detect subclinical myocardial systolic and 
diastolic dysfunction. 
In idiopathic DCM, echocardiographic myocardial deformational parameters were 
insufficiently studied. This is the case of regional myocardial function and strain rate analysis 
in patients with normalized EF after optimal pharmacologic therapy. In these patients, Okada 
M et al. demonstrated the persistence of subclinical LV dysfunction using strain rate analysis 
at rest and during exercise (186).  
We performed a prospective study including 50 DCM patients in sinus rhythm. LVRR 
occurred in 34% of them within 17.6±15.6 months and was associated with a reduced rate of 
death or HF hospitalization (5.9 % vs 33.3; p=0.03). Patients with LVRR had a final EF of 48.9 
±7.9% (Δ LVEF of 22.4%) and there was a significant decrease (p<0.05) in LVDDi, LVSD, 
LVDV, LVSV and LV mass and an increase (p<0.05) in sphericity index. However, measures of 
diastolic function (LAVi, e´velocity and E/e´ratio), final LV and RV Tei indexes and SSRcirc and 
SSRlong values were not significantly different from baseline. Even in patients in whom LVEF 
recovered to reach values of LVEF> 50%, SSRcirc and SSRlong remained below normal. 
These findings suggest that in patients with IDCM after the occurrence of LVRR 
associated with medical therapy, left ventricular function may remain abnormal, even when 
LVEF returned normal. This fact may be in favour of maintaining neuro-hormonal blockade 
even after LVEF recovery. 
 Myocardial imaging studies have demonstrated a significant decrease in LV myocardial 
longitudinal and circumferential strain, as well as in LV twist in HFrEF compared with HFpEF. 
In both in ischaemic HFrEF and DCM, besides the compromised global and regional changes in 
longitudinal deformation (more preserved longitudinal strain in the LV base compared to the 
LV apex), LV apical rotation and overall LV systolic twist are reduced, resulting in a proportional 
decrease in LVEF. In severe cases, apical rotation may be so impaired that the LV base is the 
primary determinant of overall LV twist. The LV untwist at the macroscopic level amplifies the 
elastic recoil occurring at the microscopic level due to the rapid uncoupling of actin myosin 
cross-bridges and restoration of titin molecules to their original shape (169). So, 
multidirectional myocardial analysis may be important for a better understanding of subclinical 
myocardial dysfunction in patients with HF. We didn´t perform radial strain or LV torsion due 
to software limitations; those parameters may be important for the comprehension of the 
mechanism of reverse remodeling in DCM patients. 
Foreshortened views and the assumption that speckles can be tracked from frame to 
frame, despite their out of plane motion, may affect circumferential strain measurements from 
the short-axis view. These limitations can be overcome by three-dimensional echocardiography 
and cardiac MRI. 
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1.3 Biomarkers in dilated cardiomyopathy: predictors of pharmacological 
reverse remodeling and clinical severity 
In IDCM, many biomarkers may be used to assess various pathogenic pathways, 
including neurohormonal activation, oxidative stress, interstitial matrix remodelling and 
myocyte stretch and injury. Biomarkers profile of patients with HF has been investigated to 
stratify prognosis.  Additionally it has been used in an effort to identify patients who might 
respond best to therapeutic interventions whether it is drug or device therapies (47). We 
evaluated the value of biomarkers in the prediction of the occurrence of LVRR.  
In our prospective study including 50 DCM patients BNP, 25-OH-vit D, CA 125, hs CRP, 
Lp (a) values could not predict the occurrence of LVRR.  
Patients in NYHA class III-IV, with pulmonary congestion or ankle oedema had higher 
levels of CA 125, cystatin C, BNP and hsCRP (p<0.05). CA 125 was correlated with BNP levels, 
with hsCRP and uric acid (p=0.01). BNP correlated directly with LVDD, LV volumes, PSAP, E/e´ 
and was inversely correlated to LVEF and e´velocity (p<0.05).  CA 125 positively correlated 
with LAVi, E/A ratio and PSAP (p<0.05). There was a marginal correlation between hsCRP and 
LVEF and LVDVi. We found that levels of 25-OH-Vitamin D were only correlated with PSAP and 
E/A ratio (p<0.05). 
ANP and BNP are produced in response to myocardial stretch due to pressure or volume 
overload (49). Similarly to our study the ICON study showed that HF severity, as measured by 
NYHA functional class (187) correlated directly with increasing values of BNP (188).   Also in 
alignment with our data other studies (189, 190) demonstrated that BNP and NT-proBNP 
values correlate positively with LV dimensions, LV volumes, and LV mass and are inversely 
correlated with LVEF; BNP has shown to have the strongest correlation with LV diastolic wall 
stress which is  consistent with stretch-mediated BNP secretion (189, 190). Similarly to our 
study others also showed that BNP levels increase with diastolic dysfunction severity, and 
correlate with indexes of LV filling pressure as well as with indexes of compliance and 
myocardial relaxation (191, 192). 
Serum CA 125 is a tumor marker widely used in patients with ovarian cancer (193). In 
HF it is still unclear biologic role of this substance, namely if it simply reflects an activation of 
the cytokine pathway or if it is indeed responsible for myocardial and/or skeletal muscle 
dysfunction.  In our population, CA 125 was not a predictor of LVRR, but was a predictor of a 
more severe HF presentation manifested by more severe functional class and pulmonary and 
peripheral congestion.  CA 125 correlated with measures of diastolic dysfunction: LA volume, 
E/A ratio and PSAP. It also correlated with BNP, hsCRP and uric acid values. 
CRP is a plasma protein participating in the systemic response to inflammation, a very 
important pathophysiologic mechanism of HF progression.  In our patients, hsCRP was 
associated with HF clinical severity and marginally correlated with markers of LV systolic 
dysfunction:  LVEF and LVDVi.  CRP was previously shown (194) to be positively associated 
with NYHA class and to a higher risk of HF-hospitalization and mortality.  In HF ACEI and β-
blocker therapy have been associated with lower levels of CRP (195) . Now, it remains unclear 
CHAPTER VI | DISCUSSION 
 
110 
if CRP is merely a marker of inflammation or if, on the contrary it is involved in the 
pathogenesis and the progression of HF. 
Functional vitamin D receptors are present in cardiac cells and their activation affects 
gene expression, proliferation and contraction of cardiomyocytes. In this context, vitamin D 
might contribute to the development of cardiac hypertrophy and fibrosis (196).  In our 
population, we found that 25-OH- Vitamin D was not a predictor of LVRR and only correlated 
with PSAP and E/A.  
As a conclusion, some of the biomarkers may reflect HF severity rather than a marker 
of reverse remodelling or recoverability.  
 
1.4 Extracellular matrix, inflammation and apoptosis biomarkers profile and 
left ventricular reverse remodeling  
Limited data exists regarding the usefulness of novel biomarkers to predict LVRR in 
DCM. We evaluated the potential of emerging biomarkers to predict the occurrence of LVRR.  
In a group of 50 IDCM patients we measured the levels of extracellular matrix markers 
(MMP-3, TIMP-2, ST2, Galectin-3), GDF-15 and sTNF RI at baseline and after 41.2±23.4 
months of follow-up. Patients presenting LVRR during the follow-up had lower baseline 
galectin-3 (5.61±2.98 vs 8.68±4.35ng/ml, p=0.03). During follow-up, GDF-15 increased 
(marginally) in patients with LVRR and MMP-3 increased in the overall population. GDF-15 
correlated with E/e', TIMP-2 correlated with LVDVi, LAVi and sphericity index.  
Galectin-3 is likely to play a role in cardiac remodeling, because it has a unique 
chemical structure, which makes it able to bind with extracellular matrix proteins and cell 
surface receptors (197).  In our study, a low Galectin-3 value was the only predictor of the 
occurrence of LVRR after medical therapy. Other studies demonstrated that galectin-3 has a 
negative impact on cardiac structure and function. This is in alignment with our study where 
low baseline galectin-3 values were associated with the occurrence of LV reverse remodeling 
during follow-up. We can speculate that galectin-3 blockade might favourably affect 
remodelling and can be a future target for treatment.   
In our population, MMP-3 significantly raised during follow-up both in patients with or 
without LVRR. We could not find studies on the behaviour of MMP-3 and TIMP-2 in LVRR in 
IDCM patients. There are also conflicting results regarding MMP-2 and MMP-3 levels in HF 
patients.   
In our study, TIMP-2 was positively correlated with LV diastolic volume, LV diastolic 
volume/BSA and inversely with sphericity index. Weir et al (202) analysed TIMP-1, -2, and -4 
behaviours in patients with LV remodelling and systolic dysfunction after an AMI. TIMP-2 
concentration did not correlate with any LV functional parameter or with infarct volume index 
at baseline or at 24 weeks. In this study ΔTIMP-2 did correlate with ΔLVESVI and with ΔLVEDVI 
though not with ΔLVEF or with change in infarct volume index. They observed that TIMP-2 
levels were high at baseline and increased over time. 
GDF-15 is a member of the transforming growth factor-β cytokine superfamily and 
appears to be involved in the regulation of cell differentiation and tissue repair with possible 
anti-apoptotic and anti-hypertrophic effects and is closely linked with tissue remodelling (205). 
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In the Val-HeFT study, GDF-15 levels increased over the course of 12 months in patients 
randomized to the placebo arm (203). In our study GDF-15 levels increased during follow-up, 
with non-significant lower values in patients with LVRR. We may hypothesise that this lack of 
statistical significance difference was due to a small sample size and that GDF-15 may in fact 
be able to track LVRR. In our patients, higher levels of GDF-15 correlated with worse diastolic 
function indexes (increased E/e’).  
In summary, in our study most of the baseline novel biomarkers values were lower in 
patients in whom LVRR occurred during follow-up versus those in whom it did not, but 
statistical significance was only reached in the case of galectin-3. Our study was limited by a 
small sample size, which may have obscured a possible correlation between other biomarkers’ 
values and the occurrence of LVRR.  
In our population, when comparing biomarkers basal and final levels, GDF-15 and 
MMP-3, continued to rise, despite HF therapy, even in patients with LVRR. We can speculate 
that despite LVRR, there is persistent matrix fibrosis activation, apoptosis and inflammatory 
activity. Consistent to this hypothesis are the results of The Penn Heart Failure Study, which 
included 1821 chronic HF patients (79); in the group presenting LVRR an improvement in 
prognosis was observed, nevertheless  this group still had abnormal BNP, uric acid, ST2, and 
soluble fms-like tyrosine kinase-1 and continued to experience HF-hospitalizations, suggesting 
persistent HF risk despite LVRR (79).  
We found significant correlations between CA 125 and GDF-15 and with TIMP-2; STNF 
RI, TIMP-2 and GDF-15 were also correlated with each other. This is consistent with a 
multidirectional pathway in HF pathogenesis involving cytokines, ECM activation and apoptosis.   
 
1.5  Persistence of Left Ventricular electrical remodeling despite Left 
Ventricular mechanical reverse remodeling  
According to current international HF guidelines an ICD implantation is indicated in 
patients with HF and severely depressed LVEF for the primary prevention of sudden cardiac 
death. In some patients, LVEF may improve or even normalize over time and these patients 
would no longer be qualified for ICD implantation. 
Our case report describes a patient with idiopathic DCM in whom LVEF recovery to a 
normal value occurred.  Despite this the patient had a life-threatening ventricular fibrillation, 
aborted by the ICD he had implanted when he still had severely compromised LVEF.  Despite 
the recovery of LVEF to a normal value abnormal LV strain rate and Tei index values were still 
present, indicating the persistence of subclinical LV dysfunction.  
Future advances to refine arrhythmias risk prediction may include quantification of 
myocardial fibrosis by late gadolinium enhancement on cardiac MRI imaging and myocardial 
substrate characterization by echocardiographic speckle tracking measures of global 
longitudinal strain and global circumferential strain (206).  Heterogeneity in timing of regional 
mechanical forces in the radial axis or longitudinal dispersion using strain imaging may be 
markers of risk for ventricular arrhythmias. While current prognostic and therapeutic 
recommendations are largely dependent on symptoms and on LVEF, come studies highlighted 
LGE as a crucial parameter for risk stratification and, possibly, for device implantation. Thus, 
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several advances in cardiac imaging beyond LVEF may hold promise in refining risk 
quantification for ventricular arrhythmias in DCM and aid in deciding ICD implantation.  
Multiple studies have demonstrated an association between midwall fibrosis on LGE-
CMR imaging and SCD events in patients with DCM (207)  In the study of Halliday  B et al 
(208) midwall LGE identifies a group of patients with dilated cardiomyopathy and an LVEF 
≥40% at increased risk of SCD who may benefit from ICD implantation. 
In a HF patient with an ICD, if LVEF improvement occurs and when the battery runs 
out there is an ongoing debate if we should replace the battery. Some authors suggest that 
we should not (209), whereas others think we should (210) . Chatterjee et al. (211) in a meta-
analysis including patients experiencing LV reverse remodelling after the implantation of a 
CRT-D found that patients with LVEF recovery (defined as LVEF ≥35% or ≥45%) had 
significantly lower rates of ICD therapy for ventricular arrhythmias as compared with patients 
without LVEF recovery (p= 0.001).  Nevertheless, Zecchin et al. reported that appropriate ICD 
interventions for ventricular arrhythmias occurred in 11% of CRT-D recipients who were super-
responders (LVEF >50%) to device therapy (212). This is in favour of maintaining a CRT-D 
strategy at the time of generator change in a patient experiencing LVEF. Collectively, these 
data show that approximately 20% of patients with LVEF improvement above 35% remain at 
risk of appropriate ICD therapy, but the risk appears to be lower as the EF approaches normal 
range (213). As all-cause mortality is lower in patients with improving LVEF (173), life 
expectancy is longer and so the prevention of sudden cardiac death may result in more quality 
life-years saved, favouring ICD implantation. However, this must be balanced against the 
complication rates of ICDs. 
In summary, LV mechanical reverse remodeling is not always associated with LV 
electrical reverse remodeling and an arrhythmic risk may persist.  
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2. MYOCARDIAL RECOVERY AND MYOCARDIAL REMISSION                                                                         
 
HF patients undergoing LVRR, either spontaneously or after pharmacological or device 
therapies, may follow one of two potential avenues: 1) freedom from future HF events or 2) 
recurrence of HF events.  
Taking in account these two different paths after the occurrence of LV reverse 
remodeling, Mann et al. (22) suggested that the term “myocardial recovery” should be applied 
in the case of the normalization of molecular, cellular  and LV geometric changes allowing the 
heart to maintain preserved LV structure/function in the face of normal and/or perturbed 
hemodynamic loading conditions.  
 Accumulating evidence shows that the molecular changes associated with HF, in 
particular at the transcriptome, metabolome, and ECM levels, persist in the reverse-remodelled 
myocardium despite apparent normalization of macrolevel properties (74).  
 In 2005, a transcriptome analysis of 199 human myocardial samples from failing, 
nonfailing, and mechanically unloaded hearts showed significant HF-related changes in the 
expression of >3,000 genes, however, mechanical unloading did not induce a generalized 
‘transcriptional recovery’, with only 5% of those genes showing normalization of expression 
levels after LVAD support. In addition, a new subset of genes was dysregulated in the reverse-
remodelled, LVAD-supported heart compared with normal myocardium (214). 
 LV structural and functional improvements were accompanied by a new set of 
expressed genes related to the ECM, cytoskeleton, sarcomere, and excitation–contraction 
coupling.  As more of the HF-related gene programme returned to normal values, the hearts 
had a greater capacity to withstand a second haemodynamic stress. Patients previously 
‘recovered’ can latter suffer HF recurrence due to re-emergence of HF-associated 
transcriptional abnormalities (74). 
 Matricellular proteins (osteopontin, SPARC thrombospondins, tenascin, and periostin) 
interact with cell-surface receptors, growth factors, and other ECM proteins, and function as a 
link between ECM proteins and cardiomyocytes to modulate cell behaviour.  Matricellular 
proteins levels increase in response to stress, independently of ECM and fibrillar content 
changes. Abnormalities in nonfibrillar ECM components persist after LVAD-induced reverse 
remodeling (215). 
 Taking the above into consideration, the term “myocardial remission” should be used 
to refer to the recrudescence of the molecular, cellular, and LV geometric changes that are 
insufficient to prevent the recurrence of HF in the face of normal and/or perturbed 
hemodynamic loading conditions. Although myocardial remission may be associated with 
stabilization of HF clinical course as well as reversal of many aspects of the HF phenotype, it 
is not associated with freedom from future cardiac events (22). 
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3. QUESTIONS UNANSWERED AND FUTURE RESEARCH                                                                         
 
Normal LV function is conditioned by LV double helicoidal architecture, which is determined 
by the non-contractile LV myocardial components. In concentric LV hypertrophy, the double 
helicoidal architecture is preserved resulting in normal or near normal LV twist and LVEF, 
whereas in eccentric LV hypertrophy, the double helicoidal orientation is disrupted resulting in 
decreased LV twist and LVEF. In HFrEF, therapeutic interventions that retard or inhibit ECM 
remodeling have proved effective, whereas those that increase myocardial contractility with 
no effect at ECM level are ineffective (169). It is time to start thinking of a new, 
pathophysiologically driven classification, which will take into consideration several parameters 
of LV morphology and function. 
Disease progression may also occur even in the absence of progressive cardiac remodeling. 
Although the biological motifs that separate reversible (elastic) from irreversible (plastic) 
changes in the heart are not known, it is likely that the progressive loss of cardiac myocytes, 
irreversible changes at the DNA level, and the progressive erosion of the native 3-dimensional 
organization of the ECM surrounding the cardiac myocytes will be critical determinants that 
distinguish between myocardial remission and myocardial recovery (8, 216).  
There are two ongoing randomized studies testing withdrawal of medical therapy in 
patients who recovered from DCM.  They may help to elucidate the remission versus cure   
(Withdrawal of Medication in Recovered DCM (WrecEF), Therapy withdrawal in REcovered 
Dilated cardiomyopathy trial (TRED))  (217). 
We are also pursuing the investigation into the occurrence of recurrent remodeling and the 
identification of  its causal factors and predictors. 
And what about HF with mid-range EF (HfmrEF), both HFrEF and HFpEF may evolve to 
HfmrEF, making unclear whether HFmrEF represents a transitional status between HFpEF and 
HfrEF or an independent entity on its own. Of notice is the fact that the three HF categories 
are separated by only a few LVEF percentage points, thus the inter and intra-observer 
variability of echocardiography may compromise accurate identification of borderline patients 
(170).  
Clearly the subject of reverse remodelling is an area opened to much further research, the 
result of which holds many promises. Among many others the following areas are of interest: 
1- The role of Aetiology.  
- LV remodelling and dysfunction are the common phenotypic manifestations of a 
diverse range of insults, either systemic or heart-specific. Myocardial recovery (or 
remission) can occur but is more likely to be seen in nonischaemic cardiomyopathies, 
younger patients, and patients with a more recent onset of the disease. These 
characteristics overlap with those of patients who are more likely to recover with 
therapy, including neuro-hormonal blockers, ivabradin and CRT.  
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2- The place of Advanced Echocardiography:  
- To explore the accuracy of LVEF determined by 3D imaging. 
- To characterize myocardial substrate using echocardiographic speckle tracking 
measurements of global longitudinal, radial and circumferential strain, LV torsion and 
twist.  
- To assess regional mechanical forces timing heterogeneity in radial axis and 
longitudinal dispersion, using strain rate imaging as markers for ventricular 
arrhythmias. 
- To ascertain if persistently abnormal echocardiographic global longitudinal strain can 
predict the likelihood of the occurrence LVEF decline during follow-up. 
- To assess LV contractile reserve by stress echocardiography. 
 
3- The relevance of cardiac MRI:  
- In the assessment of the impact of myocardial fibrosis and extracellular matrix 
quantification (by LGE and T1 mapping, T2 mapping and myocardial extracellular 
volume fraction) on predicting reverse remodeling. 
- In the ability to measure oedema, macroscopic fibrosis and diffuse fibrosis and to 
quantify the cellular and extracellular compartments is promising. This may allow to 
personalize therapeutic approaches and to develop new therapies targeted either to 
interstitial or to intracellular pathways. 
- In determining if the evaluation of midwall fibrosis may improve arrhythmia risk 
stratification and further refine ICD implantation criteria. 
- In studying the role of Galectin-3 and others ECM biomarkers in prediction the extent 
of replacement fibrosis at cardiac MRI. 
- In the investigation of the association between LVRR and myocardial fibrosis reversal.  
 
4- The importance of cardiopulmonary stress test:  
- In determine the impact of LVRR on exercise capacity when depressed LVEF has 
increased to 0.50 with pharmacological therapy.  
 
5- The relevance of Myocardial meta-iodobenzylguanidine imaging 
- In assessing what manner the localization and quantification of abnormalities in the 
adrenergic norepinephrine transporter terminals are associated with an increased risk 
for ventricular arrhythmia and sudden death. 
  
6- The importance of cellular/molecular studies 
- To characterize, in transgenic mouse models of reversible dilated cardiomyopathy, 
transcriptional and epigenetic changes in the myocardium during the failing and 
recovering phases. New ‘reverse remodelling genes’ are dysregulated; the function of 
these latter genes in the reverse-remodelling process is unknown. 
- To investigate the changes in mitochondrial structure and function in individuals who 
have myocardial reverse remodelling and possible recovery. 
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- To understand the changes in the ECM, incorporating the 3D structure and non-
collagen protein changes in addition to the fibrillar component, as a means to study 
myocardial stiffness and changes in myocardial recovery (74). 
- To understand whether miRNA expression patterns can normalize with reverse 
remodelling is important in the field of myocardial recovery. 
 
7 – The impact of with medical therapies 
 The effect on reverse remodelling of other experimental therapies for HF, such as 
 neuromodulation (the broad class of therapies include baroreceptor, vagal, spinal-cord 
 stimulation and cardiac contractility modulation), has not been studied; nor have the 
 effects of neprilysin inhibition. 
 
 8 – The relevance of studies on mitral percutaneous edge-to-edge repair 
 versus medical therapy on clinical end points and ventricular reverse remodelling.   
As percutaneous therapies for functional mitral regurgitation advances, with reduction 
in the risk of procedural complications and improved efficacy, the benefits of treating 
functional mitral regurgitation must be further clarified. 
 
 9- The importance of studies on effects of LVADs 
 Different LVADs have different effects on geometrical reverse remodelling: 
 intrathoracic devices tend to push the LV apex towards the base, resulting in  a more 
 spherically reverse-remodelled heart, whereas extra thoracic (pre-abdominal) 
 devices pull the LV apex away from the base, resulting in a more elliptically reverse-
 remodelled heart. 
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CONCLUSIONS                                                                                                                                                                                          
 
LVRR occurred in about one third of our idiopathic DCM patients, especially in those 
with higher blood pressure values and less advanced disease, who may benefit from maximal 
drug titration. LVRR was associated with an improvement in NYHA functional class and in 
prognosis.  
In patients with LVRR there was an improvement in diastolic and systolic volumes and 
in sphericity index.  However, despite recovery of LVEF to normal values, frequently there is 
persistent abnormal circumferential and longitudinal LV strain rate and LV Tei index values, 
suggesting sustained subclinical left ventricular dysfunction.  
CA125, BNP and hsCRP were predictors of clinical severity and congestion. A low 
baseline value of Galectin-3 may be a predictor of the occurrence LVRR. When analyzing the 
temporal evolution of biomarker levels of in our population, it became evident that some of 
them, GDF-15 and MMP-3, continued to rise, despite HF therapy, even in patients with LVRR. 
We speculate that despite ventricular reverse remodeling, there is persistent matrix fibrosis 
activation, apoptosis and inflammatory activity. Also, significant correlations were found 
between the levels of biomarkers and echocardiographic parameters of LV remodeling, 
supporting the multidirectional pathway of remodeling in HF. 
 LV mechanical reverse remodeling does not seem to be always associated with LV 
electrical reverse remodelling and thus arrhythmic risk may persist.   
Multiple lines of evidence support the point of view that in most instances, reverse 
remodeling does not lead to a normal heart, despite reversal of many aspects of the heart 
failure phenotype. Thus, the regression of the HF phenotype and the accompanying return 
toward a more normal ventricular shape and function associated with reverse remodeling does 
not signify that the cellular/molecular biology and physiology of these hearts is normal. This 
may explain why reverse remodeling may be followed by recurrence of LV dilatation and 
dysfunction with poor clinical outcomes. This is in favour of maintaining neuro-hormonal 
blockade and/or device therapy even after LVRR has occurred. 
Recognition of this new clinical phenotype, which is coming to be known as a state of 
HF remission, underscores the need to accurately define and identify reverse modelled 
myocardium in order to investigate the most appropriated therapies. 
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